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CHAPTER 1 
GENERAL INTRODUCTION 
 
Equine babesiosis is one of the most common infectious tick-borne diseases in southern 
Africa (Heerden 1996; de Waal and Van Heerden 2004). The parasites Theileria equi and 
Babesia caballi cause acute, subacute or chronic diseases in Equidae (Phipps and Phipps 
1996; Ribeiro et al. 1999; de Waal et al. 2004) or neonatal babesiosis or abortion in mares 
(Heerden 1996; de Waal et al. 2004). The disease leads to haemolytic anaemia (Schein 1988; 
Phipps et al. 1996; de Waal et al. 2004) and death can occur (de Waal et al. 2004). 
Imidocarb dipropionate is an effective treatment to control the disease in Equidae (Schein 
1988; Brüning 1996; Donnellan et al. 2003b; de Waal et al. 2004; Vial and Gorenflot 2006). 
Systemic side effects including depression, intestinal hypermotility, colic and lateral 
recumbency may occur (Adams 1981; Phipps et al. 1996). 
Additional administration of atropine (Heerden 1996; de Waal et al. 2004) or glycopyrrolate 
(Donnellan et al. 2003a; Donnellan et al. 2003b) is reported to minimise or prevent the side 
effects. 
Atropine is an anticholinergic drug that inhibits gastrointestinal motility (Ducharme and 
Fubini 1983; Adams 2001). 
Glycopyrrolate, also an anticholinergic agent, has some advantages over atropine sulphate as 
it has an increased water solubility and thus does not cross the blood-brain barrier (Donnellan 
et al. 2003b). In addition, its duration is shorter than that of atropine as it has a shorter half-
life. 
 
The induced lactose 13C-ureide breath test (LUBT) has been developed by Heine (Heine et al. 
1995)  and validated against enterocolonic scintigraphy for the measurement of oro-caecal 
transit time (OCTT) in man (Wutzke et al. 1998; Geypens et al. 1999). In horses, where 
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enterocolonic scintigraphy is not possible, the test has been validated in vitro for the 
measurement of OCTT, and has been found to be superior to the previously described 
hydrogen breath test (Sutton 2003). The induced LUBT was concluded to be a valid 
alternative to scintigraphy for measurement of OCTT in humans (Geypens et al. 1999; 
Geypens 2000) and suitable for this purpose in horses (Sutton 2003). 
 
The objectives of this study were as follows: 
 
- to improve knowledge of the specific effects of imidocarb treatment on oro-caecal 
transit time in horses 
 
- to quantify the effects of premedication with atropine or glycopyrrolate on small 
intestinal motility 
 
- to develop/validate a clinical protocol for treatment of babesiosis that results in 
minimal gastrointestinal complications 
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CHAPTER 2 
LITERATURE REVIEW 
 
This review details aspects of equine babesiosis including treatment, with emphasis on 
imidocarb, and pharmacological aspects of atropine and glycopyrrolate. It continues with a 
brief overview on the gastrointestinal anatomy of the horse and stable isotope breath tests 
with the lactose 13C-ureide breath test in particular. Further, certain aspects of stable isotopes 
and isotope ratio mass spectrometry are detailed. 
 
2.1 EQUINE BABESIOSIS 
2.1.1 Historical background 
De Waal and Van Heerden’s (2004) review mentions that Wiltshire in 1883 described the first 
recorded case of equine babesiosis in South Africa, referred to as “anthrax fever”. A similar 
condition was observed and named “biliary fever” in the Cape by Hutcheon. Nunn regarded it 
as the “bilious form” of African horse sickness. However, Hutcheon considered biliary fever 
to be a different disease. The same disease was described as equine malaria in West Africa. In 
1901 to 1902 it was demonstrated by Theiler that biliary fever is not identical to African horse 
sickness, but may occur concurrently to it (de Waal et al. 2004). An organism called 
Piroplasma equi was found by Laveran in 1901 (Schein 1988; de Waal et al. 2004; Uilenberg 
2006), having examined blood smears from South African horses (Schein 1988; de Waal et al. 
2004) from Theiler. After some controversy over the years about the classification of this 
organism, it was eventually placed in the genus Theileria (de Waal et al. 2004; Uilenberg 
2006). Koch in 1904 identified two morphologically different equine Babesia spp. in 
Zimbabwe, which were later demonstrated by Nuttall and Strickland as being causative agents 
of equine babesiosis (de Waal et al. 2004). The name Piroplasma caballi was suggested for 
 13
LITERATURE REVIEW 
the larger of the two parasites (Schein 1988; de Waal et al. 2004). They also demonstrated 
that no cross-reaction exists between these two parasites. 
For many years little effort was made to determine which Babesia species caused the clinical 
signs of infection. Over time however, distinct differences in morphology, life cycle, vectors 
and susceptibility to chemotherapy became evident between the two parasites (de Waal et al. 
2004). 
 
Holbrook (1969) reviews that equine piroplasmosis was diagnosed as a mixed infection of 
Babesia caballi and Theileria equi in Florida, following the importation of 30 ponies from 
Cuba. In 1961, a parade horse of the Miami Police Department was diagnosed with Babesia 
caballi. In 1962, when the disease occurred in most of southern Florida, the tropical horse tick 
Dermacentor nitens was proven to be a vector. Since 1962, equine babesiosis has occurred 
regularly in Florida, which has lead to a build-up of infection within the vector and host 
population. By 1969 the disease had reached a state of stability in southern Florida, with most 
of the horses being low-level carriers (Holbrook 1969). 
 
2.1.2 Background 
Equine babesiosis, also known as biliary fever or equine piroplasmosis, is one of the most 
common infectious tick-borne diseases in southern Africa (Heerden 1996; de Waal et al. 
2004). The intra-erythrocytic protozoa Theileria equi and Babesia caballi cause an acute, 
subacute or chronic disease in Equidae (Phipps et al. 1996; Ribeiro et al. 1999; de Waal et al. 
2004). It also causes neonatal babesiosis and abortion in mares (Heerden 1996; de Waal et al. 
2004). Horses, donkeys and zebras are all susceptible to both Theileria equi and Babesia 
caballi infections, although clinical cases occur mostly in horses (Schein 1988; Heerden 
1996; de Waal et al. 2004). In general, Babesia caballi infections are clinically milder and 
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less common than those caused by Theileria equi (Phipps et al. 1996; Donnellan et al. 2003b; 
de Waal et al. 2004). 
 
A lymphocytic stage of schizogony of Theileria equi in the mammalian host prior to the intra-
erythrocytic stages has led to discrepancies in the classification of this parasite (Phipps et al. 
1996; de Waal et al. 2004) and phylogenetic studies using small subunit ribosomal RNA 
(sRNA) suggest a distinct paraphyletic group for Theileria equi (Brüning 1996). Uilenberg 
(2006) suggests a classification to the genus Theileria for Theileria equi, due to the existing 
extra-erythrocytic multiplication, which often results in four merozoites and the occurrence of 
only transstadial transmission (Uilenberg 2006). 
Equine babesiosis is one of the major reasons for the prohibition of importation of horses 
from South Africa into other countries (de Waal et al. 2004). 
 
2.1.3 Aetiology and life cycle 
The genus Babesia belongs to the phylum Apicomplexa, class Sporozoasida, subclass 
Coccidiasina, order Eucoccidiorida, suborder Piroplasmorina and family Babesiidae (de Waal 
et al. 2004). Babesia equi has, after some years of controversy, been reclassified as Theileria 
equi (Mehlhorn and Schein 1998). The life cycle of Babesia spp. can be separated into three 
stages. The initial gamogony is a sexual stage in which gametes format and fuse inside the gut 
of an infected tick. This stage is followed by sporogony, an asexual reproduction in the 
salivary gland of the intervertebrate host. It is further followed by merogony, an asexual 
dividing stage inside the vertebrate host’s erythrocytes or in the case of Theileria equi also 
inside the lymphocytes (Vial et al. 2006). 
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2.1.3.1 Theileria equi 
Theileria equi is smaller than Babesia caballi (Mehlhorn et al. 1998; de Waal et al. 2004) and 
unlike other Babesia spp. has a stage of schizogony in the vertebrate host’s lymphocytes  
(Schein 1988; Brüning 1996; Uilenberg 2006). The parasite develops within five days to 
sporozoites in the salivary gland of the infected tick vector (Schein 1988; de Waal et al. 
2004). This occurs after the infected adult tick has attached to a vertebrate host (Schein 1988; 
de Waal et al. 2004; Uilenberg 2006). Transstadial transmission occurs by injection of the 
infected saliva into the host. In this case the infected tick loses its theilerial infection after 
transmission (Uilenberg 2006). 
Twelve to 14 days after infected ticks first attach, merozoites are released to invade 
erythrocytes. Trophozoites, dividing forms and merozoites occur in the intra-erythrocytic 
stage. The merozoites occur either as two or four, in a maltese cross formation and are seen as 
pyriform parasites within the erythrocyte (Schein 1988; Vial et al. 2006). 
 
2.1.3.2 Babesia caballi 
The development of Babesia caballi is found exclusively in the vertebrate host’s erythrocytes 
(Schein 1988; Brüning 1996; de Waal et al. 2004). Within the host’s red blood cells, the 
pyriform merozoites are often found as pairs with an acute angle (Schein 1988; de Waal et al. 
2004). This parasite causes usually a very low parasitaemia of less than 0.1 per cent of 
infected erythrocytes (de Waal et al. 2004). 
 
2.1.4 Distribution 
Theileria equi and Babesia caballi occur in Spain (Camacho et al. 2005), Portugal, France, 
Belgium, Poland, in large parts of the former USSR (Joyner et al. 1981) and Italy (Schein 
1988; de Waal et al. 2004). Babesiosis occurs also in Asia (Donnelly et al. 1980), the Middle 
East (Hailat et al. 1997) and is endemic in China (Xu et al. 2003) and in Mongolia 
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(Boldbaatar et al. 2005). Furthermore it has been reported from the Carribean (Rampersad et 
al. 2003) and is distributed in Africa (Gummow et al. 1996; Heerden 1996; de Waal et al. 
2004), Central (Madden and Holbrook 1968; Carbrey et al. 1971) and South America 
(Ribeiro et al. 1999), Florida (Holbrook 1969) and some regions in Australia (Schein 1988; de 
Waal et al. 2004). 
It is generally thought that the geographical distribution of equine babesiosis is dependent on 
the distribution of the requisite tick vectors (Donnellan et al. 2003b; de Waal et al. 2004). 
Gummow et al. (1996), on the other hand, reported no correlation between the prevalence of 
equine babesiosis and the distribution of tick vectors in South Africa (Gummow et al. 1996). 
Dermacentor species transmit only Babesia caballi in Central Europe, Central Asia (Phipps et 
al. 1996) and Florida (Frerichs et al. 1969), whereas Rhipicephalus evertsi evertsi transmit 
both Theileria equi and Babesia caballi in Africa (Heerden 1996; Phipps et al. 1996) and only 
Theileria equi in South Africa (de Waal et al. 2004). Rhipicephalus bursa is reported to be a 
vector of both parasites in Southern Europe and Asia Minor (Phipps et al. 1996). 
Rhipicephalus sanguineus has been reported to transmit Theileria equi and Babesia caballi 
and Rhipicephalus turanicus Theileria equi in South Africa (de Waal and Van Heerden 2004). 
Hyalomma species transmit Theileria equi and Babesia caballi in Southern Europe, Middle, 
Near and Far East and in North Africa (Phipps et al. 1996). Hyalomma truncatum is 
responsible for the transovarial transmission of Babesia caballi in Southern Africa (Donnellan 
et al. 2003b; de Waal et al. 2004). 
Furthermore, Boophilus microplus is reported to transmit Theileria equi to susceptible 
animals (Guimaraes et al. 1998; de Waal et al. 2004). 
Northern Europe, the UK, Eire and New Zealand are among the few regions from where the 
disease has not been reported (Donnelly et al. 1980; Phipps et al. 1996). 
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2.1.5 Infection 
Transmission of Babesia species occurs via the bite of an infected tick and transmission of the 
infective stage to the mammalian host via the salivary fluid (Phipps et al. 1996; Uilenberg 
2006; Vial et al. 2006). The transmitting tick is only infective a few days after attachment and 
after maturation of the sporozoites within it (Uilenberg 2006). Depending on the vector tick, 
the incubation period varies between two to ten, and up to 21 days (Mehlhorn et al. 1998). 
Theileria equi follows only a transstadial transmission (Phipps et al. 1996; Mehlhorn et al. 
1998; Uilenberg 2006). Babesia caballi infection can be transmitted transstadially by 
Rhipicephalus evertsi evertsi and transovarially by Hyalomma truncatum. Furthermore, an 
infection can occur after inoculation of infected blood into susceptible animals, as well as 
after the use of contaminated hypodermic needles. However, mechanical transmission by 
haematophagous insects has yet to be proven (Donnellan et al. 2003b; de Waal et al. 2004). In 
utero infection of equine fetuses by both Babesia species has been reported (Schein 1988; 
Phipps et al. 1996; de Waal et al. 2004). 
 
2.1.6 Pathogenesis 
Theileria equi is highly pathogenic and can infect up to 80% of erythrocytes (Mehlhorn et al. 
1998). Progressive anaemia is characteristic of Theileria equi infections (de Waal et al. 2004). 
Varying degrees of thrombocytopaenia, hypophosphataemia, hypoferronaemia and 
hyperbilirubinaemia are accompanied by peaks in parasitaemia (de Waal et al. 1987; de Waal 
et al. 2004). Babesia parasites depend on the red blood cells for their energy supply and the 
increased uptake of phosphorus by the erythrocytes may be responsible for the 
hypophosphataemia and the infected erythrocyte’s fragility (de Waal et al. 2004). In humans, 
hypophosphataemia has lead to adenosine triphosphate (ATP) depletion, which predisposes to 
development of haemolysis. In severely affected horses, haemolysis may lead to 
haemoglobinaemic nephrosis and uraemia. Concurrent infections, such as African horse 
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sickness and verminosis can complicate equine babesiosis and thus may lead to disseminated 
intravascular coagulopathy (de Waal et al. 2004). 
Pathogenesis in Babesia caballi infections on the other hand is related to accumulation of 
parasitised erythrocytes in small blood vessels and capillaries (Schein 1988; de Waal et al. 
2004). An acute hypotensive state may possibly cause acute death. Lung oedema has been 
associated with hyperacute infections and death in horses, as well as development of laminitis 
in some cases with gastrointestinal stasis. 
Both parasites often cause subclinical infections, which present with a decrease in packed cell 
volume and platelet count (de Waal et al. 2004). 
 
2.1.7 Clinical signs 
The seasonal activity of the adult stages of vectors predisposes to a higher frequency of 
clinical signs during summer months (de Waal et al. 2004). Clinical signs occur after an 
incubation period of five to 30 days following the bite of an infected tick (Holbrook 1969; 
Schein 1988; Phipps et al. 1996; de Waal et al. 2004). 
Babesia caballi infections are usually clinically inapparent and seldom lead to severe 
anaemia. Occasionally, it contributes to chronic inappetence, poor performance, loss of body 
weight, pale-pink mucous membranes, mild tachycardia and splenomegaly (de Waal et al. 
2004). 
A rare and peracute form results in horses being found either dead or moribund, and has been 
reported from South Africa (de Waal et al. 2004). The acute form is characterised by fever, 
anorexia, depression, icterus, haemolytic anaemia, petechial haemorrhages of the mucosal 
membranes and elevated respiratory and pulse rates (Schein 1988; Phipps et al. 1996; de 
Waal et al. 2004). Haemoglobinuria, an often described symptom of babesiosis in other 
species, is less frequently observed in equine piroplasmosis (Schein 1988; Phipps et al. 1996). 
In addition to the aforementioned symptoms, subacute cases may present with varying degree 
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of anorexia, weight loss, elevated or normal rectal temperature, increased pulse and 
respiratory rates, colic, constipation followed by diarrhoea, splenomegaly, and sometimes 
haemoglobinuria. The mucous membranes may vary from pale-pink or pale-yellow to bright 
yellow. Mild inappetance, poor performance, weight loss, splenomegaly and occasionally 
pale-pink mucous membranes and mild tachycardia are seen in chronic stages (de Waal et al. 
2004). Strenuous exercise may predispose horses to the clinical manifestation of the disease 
(Hailat et al. 1997). 
Weakness at birth or the rapid onset of listlessness as well as development of anaemia, severe 
icterus, malaise, fever and petechiae soon thereafter, characterise neonatal babesiosis in foals 
(de Waal et al. 2004). 
Nervous signs are seldom seen in equine babesiosis, but ataxia, generalised trembling and 
mild to moderate tonic-clonic spasms have been reported from young foals infected with 
Theileria equi. Further complications of equine babesiosis are acute renal failure, colic and 
enteritis, pneumonia, loss of fertility in stallions and abortion in mares (de Waal et al. 2004). 
 
2.1.8 Pathology 
Clinical pathology reveals a decrease in haemoglobin concentration, erythrocyte and platelet 
count (de Waal et al. 2004; Camacho et al. 2005), as well as neutropaenia and lymphopaenia 
in acute cases (de Waal et al. 2004). Total serum bilirubin, urea, aspartate aminotransferase 
(AST), creatine kinase (CK), γ-glutamyltransferase (GGT) and lactate dehydrogenase (LDH) 
can, particularly in Theileria equi infected horses, present increased levels and indicate 
haemolytic anaemia and centrilobular degeneration and necrosis of hepatocytes (Camacho et 
al. 2005). 
Macroscopically, equine babesiosis presents signs due to associated haemolytic anaemia and 
icterus. Common post mortem findings in acute infections include subcutaneous oedema of 
the lower body and extremities, serous exudates in all body cavities, splenomegaly (Schein 
 20
LITERATURE REVIEW 
1988; Phipps et al. 1996; de Waal et al. 2004), as well as hepato- and renomegaly (Schein 
1988; Phipps et al. 1996). Extensive kidney damage, including degeneration of the tubular 
epithelium with deposition of haemoglobin in the renal tubules, centrilobular necrosis and 
cellular infiltration of the sinusoids are often noted. Pronounced jaundice of serous 
membranes and pulmonary oedema are more prominent in Babesia caballi than in Theileria 
equi infections, whereas general lymphadenopathy has been observed in the latter (Schein 
1988; Phipps et al. 1996). 
Aborted foetuses and neonatal foals present anaemia and moderate to severe icterus, petechiae 
on visceral and serosal surfaces, hydrothorax, congestion and oedema of the lung, spleno- and 
hepatomegaly (de Waal et al. 2004). 
 
2.1.9 Diagnosis 
Diagnosis of equine babesiosis can be made from a combination of clinical signs, examination 
of stained blood smears and identification of the organism using light microscopy, serology, 
subinoculation of blood into a susceptible animal (Frerichs et al. 1969; Phipps et al. 1996; de 
Waal et al. 2004), polymerase chain reaction (PCR) (Rampersad et al. 2003; Alhassan et al. 
2005; Vial et al. 2006) or xenodiagnosis (Frerichs et al. 1969; de Waal et al. 2004). Due to 
the low parasitaemia, the demonstration of the parasite in thin blood smears is often very 
difficult (Heerden 1996; Phipps et al. 1996; de Waal et al. 2004). Thick blood smears are 
therefore a recommended technique for parasite detection, particularly with low parasitaemia 
(de Waal et al. 2004). The complement fixation test (CFT) is of preferred use (Frerichs et al. 
1969; Schein 1988; Brüning 1996; de Waal et al. 2004), helping to differentiate between 
Babesia caballi and Theileria equi infections (Madden et al. 1968; Weiland 1986). CFT in 
combination with the indirect fluorescent antibody (IFA) test is preferred for detection of 
carrier and chronic cases (Tenter and Friedhoff 1986; Weiland 1986) and for the purpose of 
screening horses before exportation to countries which are free from the disease (Schein 
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1988; Phipps et al. 1996; Brüning 1996; de Waal et al. 2004). However, limitations of both 
CFT (Phipps et al. 1996) and IFA tests (de Waal et al. 2004) include the occurrence of false-
positive and false-negative results. Another problem is the occurrence of cross-reactions in 
the CFT and IFA test (Joyner et al. 1981; Tenter et al. 1986; Weiland 1986; Brüning 1996). 
Cross reactions were not reported in an earlier study of Babesia spp. carrier horses using IFA 
test (Madden et al. 1968). 
More recently enzyme-linked immunosorbent assays (ELISA) have been used in 
experimentally infected horses, but serological cross-reactions also have been encountered 
(Weiland 1986; de Waal et al. 2004). New ELISA tests based on recombinant antigens (Katz 
et al. 2000) and specific monoclonal antibodies have been developed for the detection of both 
parasites, but although the sensitivity appears to be better than the CFT, further validation 
studies are recommended (de Waal et al. 2004). 
DNA probes have also been developed for the direct detection of Babesia spp. (Phipps et al. 
1996), which can also detect parasite DNA in the blood of infected ticks (Brüning 1996). 
Parasitaemia of Theileria equi equivalent to less than 0.0025% is detectable with DNA probes 
(Posnett et al. 1991). Recent advances in the in vitro culture method of equine babesiosis 
parasites have lead to the identification of Theileria equi and Babesia caballi in 
microscopically and serologically negative horses. It is a very sensitive method, as 
parasitaemias as low as 10-10% may be detected (de Waal et al. 2004). 
Most recently a single-round and multiplex PCR method was developed for the simultaneous 
detection of Theileria equi and Babesia caballi, which appears to be a very promising tool for 
the routine laboratory diagnosis of equine babesiosis (Alhassan et al. 2005). 
Equine babesiosis commonly occurs secondary to diseases or infections and therefore the 
possibility of an underlying disease or infection should always be kept in mind (Heerden 
1996). 
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The differences in drug sensitivity between Theileria equi and Babesia caballi make an 
accurate diagnosis of the specific parasite involved essential when choosing therapy (de Waal 
et al. 2004). 
 
2.1.9.1 Complement fixation test (CFT) 
The complement fixation test (CFT) follows the principle of fixation of complement during 
the reaction between specific antigen and antibody. After using a known amount of 
complement, a remaining unfixed amount can be detected by a separate antigen-antibody 
reaction and thus the complement fixing activity of the original serum can be measured. It is 
assessed by estimation of lysis as a percentage, i.e. 0%, 25%, 50%, 75% and 100%. These 
values are accorded as follows: 4+ to 2+ (positive result), 1+ (trace) or a complete haemolysis 
as a negative result (Brüning 1996). 
The CFT is highly specific for Babesia caballi. A reaction of at least 1+ at serum dilution of 
1:80 or greater is considered as evidence of an acute infection in a horse that has been 
exposed to the parasite within the previous six months. Late stages of the carrier state present 
a 2+, 3+ or 4+ reaction at serum dilution of 1:5. In a study done by Frerichs et al. (1996), 
antibodies did not appear until six to eight days after the parasite was observed on blood 
smears, then increased rapidly and reached a peak at 30 to 45 days. Positive CFT titer 
persisted between three and 15 months longer than the carrier state (Frerichs et al. 1969; 
Joyner et al. 1981) and up to 24 (Brüning 1996) or even 28 months in the case of Theileria 
equi (Joyner et al. 1981). However, false negative results were presented in another study 
(Tenter et al. 1986). 
 
2.1.9.2 Indirect fluorescent antibody test (IFAT) 
In the indirect fluorescent antibody test (IFAT), parasite antigens are bound to glass slides and 
allowed to react with the test sera. After adding and binding of a fluorescein-labelled anti-
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species serum, bound antibodies are visible under ultra-violet light. Sera are considered 
positive by presenting strong fluorescence at any dilution of 1:80 and above. This test is 
considered to be more sensitive than the CFT, as parasites can be detected between three to 20 
days post infection and also during the latent phase of infection (Tenter et al. 1986; Weiland 
1986; Brüning 1996). 
 
2.1.9.3 Enzyme-linked immunosorbent assay (ELISA) 
The optimised enzyme-linked immunosorbent assay (ELISA) uses either monoclonal 
antibodies or recombinant proteins (Brüning 1996; de Waal et al. 2004). In this test, 
antibodies in test sera compete with either the monoclonal antibody for the antigenic site in 
the merozoites or recombinant proteins from the parasite. A reduced colour reaction indicates 
positive titres. These tests are highly specific and sensitive (Brüning 1996). 
 
2.1.9.4 Polymerase chain reaction (PCR) 
The polymerase chain reaction (PCR) is used to amplify a sequence of DNA. Initially 
parasitic DNA has to be extracted and the resulting purified DNA is used as a template for 
subsequent PCR amplification. Specific primers for Babesia caballi and Theileria equi are 
necessary to test for the presence of DNA of these parasites. Following the PCR the presence 
and quantity of amplified DNA is tested using gel electrophoresis (Rampersad et al. 2003; 
Alhassan et al. 2005). 
 
2.1.9.5 DNA probes 
Extracted DNA from a blood sample is cut by restriction enzymes into several pieces. A 
specific DNA probe for the parasite is radiolabelled, incubated and hybridised with the 
extracted DNA. Subsequently autoradiography can be performed to screen for parasitic DNA 
(Posnett et al. 1991). 
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2.1.10 Differential diagnosis 
Equine influenza, equine encephalosis and equine infectious anaemia have to be considered 
clinically as differential diagnoses for equine babesiosis. Equid herpesvirus-1 infection or iso-
erythrolytic neonatal icterus must be distinguished in new-born foals. The former also has to 
be differentiated in cases of abortion in mares (de Waal et al. 2004). 
 
2.1.11 Immunity 
Horses can remain carriers for up to four years after an infection with Babesia caballi or 
probably life-long after a Theileria equi infection (Holbrook 1969; Schein 1988; Phipps et al. 
1996; de Waal et al. 2004). As a reservoir for infection of ticks, these animals play an 
important role in the epidemiology of equine babesiosis (Holbrook 1969; Phipps et al. 1996; 
Donnellan et al. 2003b; de Waal et al. 2004). 
Gummow et al. (1996) reported a higher prevalence of antibodies against Babesia caballi in 
colts than in fillies (Gummow et al. 1996). 
Maternal antibodies can be detected in foals up to five (Heerden 1996; de Waal et al. 2004) or 
six (Phipps et al. 1996) months of age. Foals are probably protected by passively-acquired 
immunity and non-specific factors during the first six to nine months of age (de Waal et al. 
2004). Infective tick bites usually produce only subclinical diseases during this time, with 
constant superinfections leading to a stable immunity (Phipps et al. 1996). 
In a survey in Brazil, Ribeiro et al. (1999) found antibodies in horses of all ages, although less 
prevalent in foals of six months of age or younger (Ribeiro et al. 1999). 
Cross-immunity has yet to be reported (Schein 1988; Donnellan et al. 2003b; de Waal et al. 
2004) but simultaneous infection with both species may occur (Donnelly et al. 1980). 
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2.1.12 Treatment of equine babesiosis 
Theileria equi parasites are generally more resistant to treatment than Babesia caballi (Kuttler 
1980; Schein 1988; Kuttler 1988; Lindsay and Blagburn 2001). Different drugs such as 
quinuronium derivates, acridine derivates and bizaso dyes such as trypan blue are reported to 
be effective (Kuttler 1988; Brüning 1996; de Waal et al. 2004). Less effective results are also 
reported from treatments of Theileria equi with tetracycline and oxytetracycline 
hydrochloride or parvaquone, an anti-theilarial drug (de Waal et al. 2004). The anti-theilarial 
compounds buparvaquone (Zaugg and Lane 1989) and parvaquone (Kuttler et al., 1987) 
failed to eliminate the infection in Theileria equi infected splenectomised carrier horses 
(Kuttler et al. 1987; Zaugg and Lane 1989). A recent study by Kumar et al. (2003) tested 
different anti-theilerial (parvaquone and burparvaquone) and anti-malarial (artesunate and 
arteether) drugs as well as imidocarb against an Indian strain of Theileria equi in donkeys. 
Imidocarb and a combination of arteether and burparvaquone were of similar efficacy in 
controlling Theileria equi, with reduced side effects from the drug combination compared to 
imidocarb alone (Kumar et al. 2003). Another new approach in treatment is drugs that target 
biosynthetic pathways of plasmid-derived organelles (Vial et al. 2006). Triclosan, belonging 
to the class of synthetic 2-hydroxydiphenyl ethers with broad-spectrum microbiotical activity, 
is an example of this group (Bork et al. 2003). This inhibitor had effective growth inhibiting 
effect on Babesia caballi and Theileria equi in an in vitro study (Bork et al. 2003; Vial et al. 
2006). This points to a critical role played by type II fatty acid biosynthesis within these 
parasites (Vial et al. 2006). 
 
Aromatic diamidines and related compounds, including diminazene diaceturate, amicarbalide 
diisethionate and imidocarb dipropionate have been shown to be more efficient babesiacides 
(Schein 1988; Brüning 1996; de Waal et al. 2004). Repeated treatments may be required for 
the control of Theilera equi infections as most of these compounds cannot sterilise this 
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infection (Carbrey et al. 1971; Kumar et al. 2003; Donnellan et al. 2003b; de Waal et al. 
2004). 
 
Severity of the disease and success of treatment may also depend on protozoal strain 
differences and susceptibility of the affected animal (Brüning 1996). 
Therefore, in severe cases of babesiosis, supportive therapy might be necessary. This may 
include combinations of blood (Heerden 1996) with or without fluid infusion, administration 
of vitamins (Kuttler 1988), good nutrition (Phipps et al. 1996), antibiotics, polyionic 
electrolyte infusion, oral laxatives and essential phospholipids (Brüning 1996; de Waal et al. 
2004). 
 
Treatment should never aim to sterilise the infection in endemic areas (Heerden 1996), unless 
horses are to be moved from an endemic area into one free of disease (Kuttler 1988; de Waal 
et al. 2004). 
 
Although donkeys were successfully vaccinated against Theileria equi in a recent study 
(Kumar et al. 2002), no vaccines for equine babesiosis are currently available (Brüning 1996; 
de Waal et al. 2004). Therefore control of the disease in endemic areas involves strategic 
exposure to infected ticks of young foals and subsequent regular anti-tick prophylaxis during 
their entire life (Heerden 1996; Brüning 1996). Highly sophisticated intensive management 
systems can probably eradicate the vector ticks completely and hence control the disease 
(Heerden 1996), but leave the animals with naïve immunity susceptible to subsequent 
reinfection (Vial et al. 2006). 
 
2.1.13 Imidocarb 
Although there are different babesiacidal drugs, imidocarb dipropionate is the drug of choice 
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(Vial et al. 2006) for equine babesiois (Donnellan et al. 2003b). Imidocarb dipropionate is an 
aromatic diamidine. The chemical formulae 1,3-bis[3-(4,5-dihydro-1H-imidazol-2-
yl)phenyl]urea (PubChem CID 21389 2007) or [3,3’ bis-(2-imidazolin-2-yl) carbanilide 
dipropionate] (Lindsay et al. 2001) are published. It has a widespread distribution in body 
fluids and tissue (Belloli et al. 2002). A study performed on a small sample size showed that 
imidocarb crosses the equine placenta and reaches concentrations in the foetus similar to the 
dam (Lewis et al. 1999). Plasma concentration of imidocarb was not still detectable twelve 
hours after administration of 2.4 mg/kg bwt (Belloli et al. 2002). It is recommended to be 
administered intramuscularly or subcutaneously, but not intravenously (Vial et al. 2006). The 
precise mode of action against piroplasmosis is not yet clearly understood (Simpson and Neal 
1980a; Kuttler 1988; Brüning 1996; Vial et al. 2006). It is thought to involve the compound’s 
combination with nucleic acids, causing partial uncoiling and denaturation of the DNA double 
helix of the parasite. This leads to dilation of the nuclea cisterna, karyorrhexis, cytoplasmic 
vacuolation, inhibition of food vacuole formations and ribosomal diminuation (Simpson et al. 
1980a; Kuttler 1988; Brüning 1996). Simpson et al. (1980) reported intra-erythrocytic 
crystallisation of haemoglobin in imidocarb treated horses infected with Theileria equi, but 
concluded it as of no practical consequence, since only 1 to 2% of parasitised erythrocytes 
contained crystals (Simpson et al. 1980b). 
Imidocarb also inhibits the entry of inositol into the parasitised erythrocyte and therefore 
leads to “starvation” of the parasite (Vial et al. 2006). 
 
The therapeutic dose of imidocarb dipropionate is between 2 to 4 mg/kg body weight, with 
two doses given 24 hours apart (Phipps et al. 1996). A 2 mg/kg body weight dose 
administrated at a 24-hour interval is extremely effective against Babesia caballi (Frerichs 
and Holbrook 1974; Vial et al. 2006). Belloli et al. (2002) suggest a plasma concentration 
lower than 0.3 to 0.25 µg/ml of imidocarb as sufficient (Belloli et al. 2002). The commonly 
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recommended dosage is 2.4 mg/kg body weight administered intramuscularly on two 
consecutive days. This treatment sterilises Babesia caballi infection and clinically eliminates 
Theileria equi infections (Phipps et al. 1996). In one study using imidocarb dihydrochloride at 
a dosage of 4 mg/kg body weight administered four times at 72-hour intervals, the drug was 
able to clear the Theileria equi infection in 13 of 14 horses. However, all eight donkeys in the 
study died and severe side effects such as salivation, restlessness, gastrointestinal 
hypermotility and colic occurred in the treated horses (Frerichs et al. 1973). This result may 
be explained as a consequence of differing drug susceptibility to different Babesia strains as a 
similar treatment regimen failed to clear a European strain of Theileria equi infection within 
carrier horses in another study (Kuttler et al. 1987). This is supported by Schetters et al. 
(1997), who studied European and South African strains of Babesia canis in dogs and 
demonstrated that geographically different isolates reveal different pathology (Schetters et al. 
1997). 
It is recommended to divide the treatment into two equal doses given 30 minutes apart to 
minimise the side effects of therapy (Kuttler 1988; Heerden 1996). 
 
2.1.14 Efficacy and side effects of different anti-parasitic agents 
Sterilisation of Babesia caballi infections is effectively done by several drugs, but the 
elimination of Theileria equi is very difficult (Brüning 1996; de Waal et al. 2004). 
Diminazene diaceturate, amicarbalide and imidocarb sterilise Babesia caballi. However, 
diminazene diaceturate causes swelling and necrosis at the injection sites. Toxic doses may 
result in respiratory distress, depression and other signs of intoxication (Brüning 1996; de 
Waal et al. 2004). 
 
The only report of elimination of Theileria equi was from a trial with imidocarb treatment, 
used at a dosage rate of 4 mg/kg body weight (Frerichs et al. 1973) and at 10 mg/kg body 
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weight at 72-hour intervals. However, severe side effects such as colic, diarrhoea and 
anorexia sometimes leading to death were observed (Carbrey et al. 1971; de Waal et al. 
2004). 
Meyer et al. (2005) focussed particularly on renal and liver function when examining six 
ponies following four intramuscular doses of 4 mg/kg imidocarb dipropionate given at 72-
hour intervals. They reported local irritation at the injection sites, which was also reported by 
Kumar et al. (2003), plus mild colic, depression and anorexia in some animals. Temporary 
mild renal decompensation was also a feature, but no significant deleterious effect on hepatic 
function was noted (Meyer et al. 2005). 
Even at the usual intramuscular dosage of 2.4 mg/kg body weight, colic may occur due to the 
cholinergic properties of this drug. Frerichs and Holbrook (1974) observed mild salivation 
and slightly increased gastrointestinal motility even at a dosage of 2 mg/kg body weight 
(Frerichs et al. 1974). Their study animals, on the other hand, did not show any local irritation 
at the injection site even though up to 8 mg/kg body weight of imidocarb dipropionate was 
used (Frerichs et al. 1974). 
Additional administration of atropine (Heerden 1996; de Waal et al. 2004), or glycopyrrolate 
(Donnellan et al. 2003a; Donnellan et al. 2003b) or splitting the calculated dosage of 
imidocarb into two given 30 minutes apart, is reported to minimise or prevent the side effects 
(Kuttler 1988; Heerden 1996). The toxic dose of imidocarb dipropionate in horses is close to 
10 mg/kg body weight, while the LD50 is about 16 mg/kg body weight for 21 days, 
administered intramuscularly twice at an interval of 48 hours (Adams 1981; de Waal et al. 
2004). Mortalities are due to hepatic and renal necrosis, occurring within six days after the 
first injection (Adams 1981). 
 
Imidocarb is a carbamate, causing reversible inhibition of cholinesterase (Donnellan et al. 
2003b). Intramuscular injection of imidocarb can cause local irritations such as acute 
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haemorrhagic necrosis of the skeletal muscle with clear fascial oedema and mineralised 
myositis, described as post mortem findings (Adams 1981). 
The toxicity of imidocarb dipropionate is related to its cholinergic (Donnellan et al. 2003a; 
Vial et al. 2006) plus direct nephrotoxic and hepatotoxic effects (Donnellan et al. 2003b). In 
horses, dose-dependent nephrotoxicity and hepatotoxicity is seen, with cortical tubular 
necrosis, hepatocellular necrosis and pronounced periportal hepatocellular swelling. These 
findings are similar to the toxic effects of imidocarb in dogs (Abdullah et al. 1984) and goats, 
in which species it may cause immediate transient excessive salivation and diarrhoea, 
followed by anorexia, dyspnoea, recumbency and death due to acute renal failure and uraemia 
caused by renal tubular necrosis. The hepatotoxic action of imidocarb has only minimal effect 
on goats (Corrier and Adams 1976). The recommended dosage of 4 mg/kg IV for dogs and 
goats, resulted in transient salivation for both species and diarrhoea in dogs (Abdullah and 
Baggot 1983). A study in goats reported that alterations in the disposition kinetics of 
imidocarb can occur as a result of fever and is dependent on the causative agent (Abdullah 
and Baggot 1986). 
 
Horses receiving imidocarb dipropionate at a dosage of 4 mg/kg body weight may present a 
systemic reaction, including depression, excessive sweating, extreme restlessness, salivation, 
lacrimation, miosis, serous nasal discharge, dyspnoea, violent persistalsis and excessive gut 
motility with frequent defaecation, colic and lateral recumbency lasting between 30 minutes 
and four hours (Adams 1981; Phipps et al. 1996). The symptoms could be minimised by 
giving half the calculated dose twice, 15 to 30 minutes apart (Frerichs et al. 1973). Abortion 
was not reported from Adams’ study (Adams 1981). Blood urea nitrogen, serum aspartate 
aminotransferase, serum sorbitol dehydrogenase and serum creatine phosphokinase 
concentrations are also reported to be increased after an imidocarb treatment (Adams 1981). 
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After treatment at the dosage of 2.4 mg/kg body weight, only mild transient reactions such as 
salivation, diarrhoea and abdominal discomfort are generally seen (Heerden 1996). 
Resistance to imidocarb dipropionate has been introduced in laboratories and some acute 
phases of babesiosis have not responded to this drug. Residue problems have led to the 
unavailability of imidocarb dipropionate in some areas, including Europe (Vial et al. 2006). 
 
 
2.2 ATROPINE AND GLYCOPYRROLATE 
As an alternative to splitting the administered dose of imidocarb dipropionate, side effects 
may be minimised by the prior administration of either atropine sulphate (Heerden 1996) or 
glycopyrrolate at a dose of 0.0025 mg/kg i.v. or 1ml/80 kg bwt i.v. (Donnellan et al. 2003a; 
Donnellan et al. 2003b). 
 
2.2.1 Atropine sulphate 
In a review of cholinergic drugs, Adams (2001) described atropine as a parasympatholytic 
drug that prevents acetylcholine from exerting its characteristic effects on structures 
innervated by postganglionic parasympathetic nerves. This muscarinic blocking agent is an 
alkaloid, extracted from the Belladonna plants. Chemically, it consists of the organic base 
tropine, which is bonded through an ester linkage to tropic acid. 
Atropine interacts with muscarine receptors of effector cells and by its occupation prevents 
acetylcholine from binding to the receptor. Large amounts of acetylcholine or other 
cholinomimetic drugs can push atropine aside by competitive binding. Different parts of the 
body have different susceptibilities to the drug. Therefore salivary and cholinergic sweat 
glands need only a small amount of atropine to be affected, whereas the heart, gastrointestinal 
tract and urinary tract require larger dosages (Adams 2001). 
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Cardiovascular effects of atropine include an increased pulse rate and a raised cardiac output. 
The blood pressure either remains unchanged or increases slightly. Atropine, when given in a 
large dose, is directly depressant to the myocardium and also causes cutaneous vascular 
dilatation (Adams 2001). 
 
By inhibiting the contractile effects of cholinergic nerve impulses, atropine also causes a 
relaxation of the smooth muscles of the gastrointestinal (GI) tract. It clearly decreased the 
myoelectrical and myomechanical activities in the jejunum and pelvic flexure in a study using 
impedance monitoring of equine intestinal motility (Lamar et al. 1984). Atropine induces a 
significant decrease in the amplitude of contractions, but not their frequency in the equine 
jejunum (Malone et al. 1996). This action has been used in the treatment of intestinal spasm 
and hypermotility (Adams 2001), although Ducharme and Fubini (1983) recommend that it 
should not be used for the relief of gastrointestinal spasm (Ducharme et al. 1983). Roberts 
and Argenzio (1986) suggest also that the use of atropine in colic and diarrhoea is 
contraindicated (Roberts and Argenzio 1986). 
Atropine has also shown to delay gastric emptying of liquids in man and to reduce 
antroduodenal motor activity (Imbimbo et al. 1990). 
Secretions from the GI tract and from the salivary glands will be markedly reduced by 
atropine. By administration of exceedingly high doses, atropine may also decrease gastric 
secretion (Adams 2001). Donnellan et al. (2003) reported in their study a significant reduction 
of gastrointestinal motility in horses after co-administration of atropine (Donnellan et al. 
2003a). Williams et al. (2000) showed in their study that even topical and subconjunctival 
atropine application decreases gut motility (Williams et al. 2000). 
 
In the respiratory tract, atropine administration leads to a decreased secretion and 
bronchodilatation, which also gives temporary symptomatic relief from acute dyspnoea in 
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horses with recurrent airway obstruction (Adams 2001). It can be used as a diagnostic test in 
the diagnosis of heaves (Robinson et al. 2001). Atropine also affects the ocular, urinary and 
central nervous systems (CNS), where it causes mydriasis and cycloplegia, urine retention, 
and mania and excitement, respectively. It is therefore contraindicated in the presence of 
increased intraocular pressure from acute angle glaucoma (Adams 2001). Mydriasis and 
possibly CNS stimulation may be seen as atropine crosses the blood-brain barrier (Donnellan 
et al. 2003b). 
 
Clinically, atropine can be used to control smooth muscle spasm; to antagonise excessive 
cholinergic stimulation, in conjunction with morphine to reduce salivary secretion (Adams 
2001); to prevent bradycardia and the second degree heart block in horses induced by 
xylazine (Adams 2001) or romifidine (Gasthuys et al. 1990), and to decrease the dose 
requirement of dobutamine in horses anaesthetised with detomidine and halothane (Weil et al. 
1997). Atropine can also facilitate ophthalmoscopic examination, although it has been 
superceded by shorter-acting compounds. Furthermore it is used in preventing or breaking 
down adhesions between lens and iris and is also an essential antidote to anticholinesterase 
intoxication (Adams 2001). 
 
Species are less susceptible to the toxic effects of atropine when it is given orally. Herbivora 
are usually more resistant to atropine toxicity than Carnivora. Clinically, an atropine 
poisoning case may present with dry mouth, thirst, dysphagia, constipation, mydriasis, 
tachycardia, hyperpnoea, restlessness, delirium, ataxia and muscle trembling. In severe cases, 
convulsions, respiratory depression and respiratory failure lead to death (Adams 2001). 
 
One of the major aims of this study was to quantitate the effect of atropine administration on 
equine orocaecal transit time, and to study its interaction with imidocarb dipropionate on this 
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parameter. The effect of atropine on transit of solid phase material has not previously been 
determined in the horse, and was investigated in this study using the lactose 13C-ureide breath 
test, a novel test involving stable isotope technology. 
 
2.2.2 Glycopyrrolate 
Glycopyrrolate, a quaternary nitrogen compound, is also an anticholinergic agent but has 
some advantages over atropine sulphate and has found attention for preanaesthetic use in 
veterinary medicine (Singh et al. 1996; Adams 2001). It has an increased water solubility and 
thus does not cross the blood-brain barrier (Donnellan et al. 2003b). The tachycardic response 
associated with muscarinic block at the sinoatrial node seems to be a lesser problem with 
glycopyrrolate such that a dose of 2.5 µg/kg was reported not to influence the heart rate 
(Singh et al. 1997a). In addition, ocular effects are not seen with glycopyrrolate, as it does not 
cross the blood-brain barrier (Singh et al. 1997a). 
In comparison to atropine sulphate, the reduced secretions within the respiratory tract and 
lesser penetration of the blood-brain barrier also make this drug a safer alternative (Adams 
2001). Horses given glycopyrrolate prior to imidocarb administration showed the same 
gastrointestinal motility as a saline control group in a recent study (Donnellan et al. 2003a) 
when estimated according to ultrasonographic assessment of large bowel motility. Hence 
prior administration of glycopyrrolate may be preferable to atropine for minimising or 
preventing the side effects associated with imidocarb treatment. 
Singh et al. (1996) evaluated the effect of glycopyrrolate as premedication to 
xylazine/ketamine-induced anaesthesia. They reported a significantly reduced cardio-vascular 
dysfunction by using glycopyrrolate and a delayed return to normal gastrointestinal motility 
without causing any side effects (Singh et al. 1996). 
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The effects of glycopyrrolate (Singh et al. 1997a) and atropine (Roberts et al. 1986) are dose 
dependent. 
 
In this study, the effects of imidocarb dipropionate on equine intestinal motility, and the 
relative effects of atropine or glycopyrrolate premedication were quantified using stable 
isotope breath test technology. Pharmacological effects on oro-caecal transit time were 
studied using the induced lactose 13C-ureide breath test (LUBT) (Geypens et al. 1999; Sutton 
et al. 2002; Sutton 2003). The primary objective of this study was to determine the optimum 
premedication strategy for equine babesiosis in order to minimise the gastrointestinal 
complications associated with treatment. 
 
Semi-quantitative studies of gastrointestinal motility using transabdominal ultrasonography 
have suggested that the effect of imidocarb on gut motility is best ameliorated by 
premedication with glycopyrrolate (Donnellan et al. 2003a; Donnellan et al. 2003b). As non-
invasive quantitative stable isotope tests have now been validated for the measurement of 
equine oro-caecal transit time, this study aims to quantify the effects of treatment modalities 
on this specific parameter of intestinal transit. 
 
 
2.3. BRIEF OVERVIEW OF EQUINE GASTROINTESTINAL ANATOMY AND 
PHYSIOLOGY 
2.3.1 The equine stomach 
The single chambered equine stomach is relatively small and has a physiological capacity of 
eight to 15 l. It lies with its largest part in the left dorsoproximal cranial abdomen and is 
bordered by the spleen, diaphragm, liver, jejunum, descending colon, the diaphragmatic 
flexure of the large colon, the right ascending colon and the pancreas (Nickel et al. 1979). 
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It consists of four histologically different regions of mucosal lining. The Pars 
proventricularis (Nickel et al. 1979) is the oral half, similar to the oesophagus and lined by 
squamous mucosa without any glandular structure. There is the absence of active transport 
processes. The margo plicatus marks the border between the squamous mucosa and the 
narrow strip of glandular mucosa that presents the cardiac gland region (Merritt 1999) or Pars 
glandularis (Nickel et al. 1979). Although numerous somatostatin-immunoreactive cells can 
be found there, playing an important rule in endogenous control of gastric acid secretion, little 
is known about the function of this glandular region. Along the greater curvature and up the 
sides to where the junction with the cardiac gland mucosa occurs, there is the fundic gland 
region. This gastric region includes parietal cells secreting hydrochloric acid (HCL) and 
zymogen cells producing pepsinogen, as well as enterochromaffin-like (ECL) cells that may 
secrete histamine in addition to proven serotonin production. The gastric antrum is lined by 
the pyloric gland region, which is the main source of gastrin, produced by G-cells. 
Furthermore somatostatin and serotonin are produced there by D- and ECL-cells, respectively 
(Merritt 1999). 
 
2.3.2 The small intestine 
The stomach empties into the small intestine, which consists of the duodenum, jejunum and 
ileum with a length of 1 m, 25 m and 70 cm, respectively. The duodenum lies next to the liver 
and traverses between the right lobe of the liver and the ascending colon along the caecal 
base. At the duodenojejunal flexure the duodenum ends at the jejunum which is held in 
position by the mesenteric root. The jejunal tubes are mixed with the tubes of the descending 
colon in the left dorsal abdomen. The jejunum ends at the ileum in the left caudal abdomen, 
moves into the right caudal abdomen and ends with the Ostium ileale into the caecum (Nickel 
et al. 1979). 
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Myoelectrical recording has shown that the small intestinal migrating myoelectrical complex 
(MMC), a pattern of electrical activity, consists of three phases that last approximately 90 min 
and reoccur cyclically in horses. Unlike other species, MMC activity is not disrupted by ad 
libitum feeding. Phase I is a quiet period, showing no action potential (AP) activity. Phase II 
presents intermittent AP activity and is that period during which most of the transit of 
intestinal content occurs. Phase III has the most intense and continuous AP activity and is 
most prominent in the equine duodenum (Merritt 1999). 
Brush border enzyme activity is responsible for the hydrolysis of disaccharides in the equine 
small intestine. The lactase enzyme neutral ß–galactosidase declines in activity from birth to 
three years of age and disappears completely thereafter, leading to an inability of lactose 
digestion and absorption in adult horses (Roberts 1975). 
 
2.3.3 The caecum and large colon 
The caecum fills a major part of the right abdomen and has an average length of 1 m and a 
capacity of 16 to 68 l, with an average of 33 l, consisting of a caecal head, caecal body and 
caecal apex with several haustra. Through the Ostium caecocolicum it ends into the ascending 
colon (Nickel et al. 1979). 
Ross et al. (1986) observed a haustra-to-haustra mixing movement involving the caecal body 
and caudal caecal base once every four minutes. This coordinated contraction, starting in the 
caecal body, was reported to push ingesta forward into the caecal base, and from there via the 
caecocolic orifice into the right ventral colon (Ross et al. 1986). 
A pacemaker region, supposedly located in the caecal body near the apex, is thought to be 
responsible for caecal emptying and initiation of aboral peristaltic activity of the right ventral 
colon. Existing retropulsion of the right ventral colon, independent of caecal activity, was 
confirmed in a study investigating normal motility of the caecum and the right ventral colon 
 38
LITERATURE REVIEW 
(Ross et al. 1986) suggesting the presence of a further discrete pacemaker region for colonic 
activity. 
Simmons and Ford (1990) reported a liquid flow from the caecum of 54.2 ± 1.89 l/d and from 
the large colon of 49.9 ± 1.25 l/d in ponies. The capacity of the caecum and large colon were 
7.0 l ± 0.8 (SE) and 17.7 l ± 3.7 (SE), respectively (Simmons and Ford 1990). 
Bacterial isolates from the equine caecum presented as 50.9% gram-negative rods, 22.8% 
gram-positive rods and 21.9% gram-positive cocci (Maczulak et al. 1985). Only 18% of these 
isolates were reported to use urea for growth and urease activity was detected in 2 of 114 
isolates only. An explanation for the low number of ureolytic bacteria isolated was that either 
a low number of ureolytic bacteria might exist in the equine caecum, or that urease activity is 
related to the caecum wall and thereby excluded due to the sampling procedure of this study 
(Maczulak et al. 1985). 
 
The ascending colon has a length of 3 to 4 m and a capacity of 55 to 130 l and lies in a U-
formation in the abdominal cavity. It leads from right caudoventral to cranial, building the 
diaphragmatic flexure, towards the left, from cranial to caudal. There it bends backwards 
again, building the ventral and dorsal parts of the pelvic flexure before leading into the right 
dorsal colon. Near the 17th to 18th thoracic vertebra it ends at the transverse colon, a short part 
of the colon which pulls towards the craniodorsal left abdomen and leads into the descending 
or small colon. The small colon (2.5 to 4 m long) lies in the left craniodorsal abdomen and 
later ends close to the pelvis at the short rectum (Nickel et al. 1979). 
The circular and longitudinal muscle layers of the equine colon are directly coupled 
electrically. They act as a pacemaker in the area of the pelvic flexure for retropulsion-
propulsion events (Sellers et al. 1982). However, this pacemaker theory is questioned by other 
authors, who found out that there is a greater activity at the pelvic flexure area and the left 
ventral colon during a fed than a fasted state (Merritt et al. 1995). 
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2.3.4 Large colon and caecal impaction 
Both caecal and colonic neuronal deficit has been reported as a cause of disordered motility of 
these sections of intestine, resulting in chronic or recurrent impactions. Schusser et al. (2000) 
reported that caecal neuronal density was decreased in those horses that suffered from 
recurrent caecal impaction, and suggested an hereditary basis (Schusser et al. 2000). NSAIDs 
have also been associated with large colon as well as caecal impaction by suppressing 
prostaglandin synthesis. A selective COX-2 inhibitor is suggested to preserve COX-1 activity 
and therefore maintain constitutive prostaglandin levels and intestinal contractility, but further 
research is needed (White 2000). 
 
 
2.4 Stable Isotope Breath Tests 
2.4.1 Background and Principles
Stable isotope breath tests provide an indirect and non-invasive means of testing 
gastrointestinal function. The main general principle of breath tests is that a metabolic 
reaction or a physiological process can be studied by measuring the rate of appearance of 
metabolites of a labelled test substrate in exhaled breath. This metabolite can either be 
hydrogen gas, produced by bacterial fermentation, or carbon dioxide from endogenous 
metabolism (Halliday and Rennie 1982). The choice of 13C labelled substrate determines the 
specific physiological process that is studied. The rate of increase in 13C:12C ratio in exhaled 
breath provides an indirect measure of the physiological process under study, as long as this is 
the major rate-limiting stage in the metabolism of the specific 13C-labelled isotope 
administered. The dose, the 13C enrichment of the substrate and the degree of metabolic CO2 
production all influence the enrichment of 13C during a breath test (Stellaard and Geypens 
1998). 
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Breath tests are used extensively in human gastroenterology for evaluation of small intestinal 
bacterial overgrowth and lactose intolerance (Bracher and Baker 1994; Romagnuolo et al. 
2002), carbohydrate malabsorption, assessment of gastrointestinal motility and investigation 
of food digestibility (Bracher et al. 1994), effects of drugs on oro-caecal transit time (OCTT) 
(Staniforth 1987), pancreatic and hepatic function (Koletzko et al. 1997; Kalivianakis et al. 
1997; Romagnuolo et al. 2002) and for diagnosis of Helicobacter pylori (Koletzko et al. 
1997; Romagnuolo et al. 2002). However, the evaluation of liver and pancreatic function by 
specific breath tests is yet to be recommended for routine clinical diagnostic use 
(Romagnuolo et al. 2002). 
 
2.4.2 13C-Octanoic Acid Breath Test (13C-OABT) 
The 13C-octanoic acid breath test (13C-OABT) has been reported for the evaluation of gastric 
emptying rate in dogs (Wyse et al. 2003), ponies (Wyse et al. 2001) and horses (Sutton 2003) 
in addition to its routine diagnostic use in people (Schwabe et al. 1964; Ghoos et al. 1993; 
Maes et al. 1994; Choi et al. 1998; Van Den Driessche 2001). The underlying principle of the 
13C-OABT is that, following ingestion of a 13C-octanoate labelled test meal, the rate of 
increase in expiratory 13C:12C ratio forms an indirect measure of the rate of solid phase gastric 
emptying of that meal (Ghoos et al. 1993). 13C-octanoic acid is a medium chain fatty acid 
(MCFA). After leaving the stomach and subsequently the intestinal mucosa, MCFAs follow 
the portal venous system and reach the liver rapidly. After entering the Krebs cycle, 13CO2 
will be generated that equilibrates with the body bicarbonate pool, undergoes respiratory 
pulmonary exchange and causes a consequent increase in expiratory 13C:12C ratio (Bach and 
Babayan 1982). Measurement of this change in expiratory 13C:12C ratio can be used to 
provide an indirect measure of the rate of gastric emptying as this has been demonstrated to 
be the major rate-limiting determinant of this process. Metabolism of the 13C-octanoate 
otherwise proceeds at a constant rate in the healthy individual. 
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Lee et al. (2000) more recently validated the [13C] Spirulina platensis breath test against the 
gold standard technique of scintigraphy in man as being a suitable indirect method for 
determination of gastric emptying rate (Lee et al. 2000b). They further investigated a 
simplified approach of the 13C-octanoic acid breath test for the measurement of gastric 
emptying in diabetics (Lee et al. 2000a). Recently, a promising preliminary study was 
published using natural 13C and the cheaper non-dispersive infrared spectrometry-analysis in 
man (Jonderko et al. 2005) for the assessment of gastric emptying rate. 
 
2.4.3 Measurement of Oro-Caecal Transit Time 
The symptoms of many gastrointestinal disorders may be secondary to small intestinal 
dysmotility. Techniques have been developed to assess oro-caecal transit time (OCTT) as an 
indirect measure of small intestinal transit. Gastroenterocolonic scintigraphy is used as the 
“gold standard” for measurement of OCTT in humans. The application of gastroenterocolonic 
scintigraphy is not possible in horses due to the large size of the equine abdomen and imaging 
difficulties. 
OCTT is the time required to travel from the mouth to the arrival of the head of the column of 
ingesta in the caecum, and depends on the gastric emptying rate as well as the small intestinal 
transit time (Miller et al. 1997). 
Grain ingestion may be responsible for a delay in gastrointestinal transit in horses (Lopes et 
al. 2004). Caloric content of a test meal shows influence only on gastric emptying. Gastric 
emptying and small intestinal transit seem to compensate each other, as a slow gastric 
emptying is not followed by a slow small intestinal transit in healthy subjects (Geypens 
2000). The protozoal population of the caecum is not affected by the diet (Moore and 
Dehority 1993). 
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2.4.3.1 Hydrogen Breath Tests (H2BT) 
Hydrogen breath tests (H2BT) have been performed in cats for evaluating the effect of age 
(Papasouliotis et al. 1998) or sedation (Sparkes et al. 1996) on OCTT, and also in horses 
(Murphy et al. 1998; Sutton 2003), ponies (Wyse et al. 2001), rats (Brown et al. 1987) and 
humans (Camboni et al. 1988; Sciarretta et al. 1994; Miller et al. 1997; Casellas and 
Malagelada 1998) for the assessment of this parameter. The principle of the H2BT is based on 
the fact that carbohydrates not digested in the small intestine will be broken down in the large 
colon by intestinal bacteria. Hydrogen (H2) is produced by this large intestinal microbial 
fermentation and subsequently exhaled in measurable quantities in breath, providing an 
indication of the arrival of undigested material in the caecum (Levitt 1969). The H2BT is 
reported to be poorly reproducible (Ladas et al. 1989) and some H2 non-producers were 
found, in which OCTT could not be determined effectively (La Brooy et al. 1983; Ladas et al. 
1989; Sutton et al. 2000). The H2BT produced significant shortening of OCTT in healthy 
humans, caused transit disorders and was therefore unreliable in OCTT measurements. In 
addition, Murphy (1998) noted that the lactulose H2 breath test is highly variable in the 
measurement of OCTT in ponies and recommended further research until the test could be 
reliably applied for examination of gastrointestinal (GI) function (Murphy et al. 1998). 
Miller et al. (1997) showed that lactulose slowed gastric emptying, but significantly increased 
small intestinal motility and decreased OCTT (Miller et al. 1997). 
Overall, the H2BT has been used for the indirect measurement of OCTT, but has been shown 
to be inferior to other breath test techniques. 
 
2.4.3.2 Sulphasalazine/Sulphapyridine (SLZ/SP) Test 
The sulphasalazine/sulphapyridine (SLZ/SP) test has been used for the measurement of 
OCTT in man (Kellow et al. 1986; Staniforth 1989), dogs (Papasouliotis et al. 1995) and 
horses (McGreevy and Nicol 1998). Sulphasalazine (SLZ) is produced by the azo-bond 
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coupling of sulphapyridine with 5-aminosalicylic acid. It cannot be absorbed in the small 
intestine as it requires bacterial cleavage of the azo-bond in the large intestine. Once released 
in the large intestine, the sulphapyridine (SP) is rapidly absorbed and undergoes hepatic 
conjugation to various metabolites (Kellow et al. 1986). The SLZ/SP test requires the 
collection of multiple blood samples and subsequent analysis by high performance liquid 
chromatography. Using the SLZ/SP test, equine OCTT was reported to be prolonged in crib-
biting individuals if these individuals were prohibited from performing their stereotypical 
behaviour (McGreevy et al. 1998). McGreevy et al. (2001) reported also when using the 
SLZ/SP test that equine OCTT was relatively reduced in crib-biting horses compared with 
normal individuals (McGreevy et al. 2001). Further disadvantages of the SLZ/SP test for 
equine use are that no standard technique for OCTT measurement has yet been validated 
against this test, and that pharmacokinetics and therapeutic indices of SP have yet to be 
established in the horse. 
The fact that multiple blood sample collections are required, and that analytical techniques are 
difficult, makes the SLZ/SP test less attractive for routine measurement of equine OCTT. 
 
Both the H2BT and the SLZ/SP test have been used for the measurement of equine OCTT. 
However, both have a number of potential problems and require further validation. 
Gastroenterocolonic scintigraphy has been adopted as the gold standard technique for OCTT 
assessment in humans. This technique has limited accuracy in the horse, and a true “gold 
standard” for the non-invasive measurement of equine OCTT has yet to be accepted. 
 
2.4.3.3 Induced Lactose 13C-Ureide Breath Test (LUBT) 
The induced lactose 13C-ureide breath test (LUBT) was first proposed by Heine et al. (1994) 
to be a suitable test for measurement of human OCTT (Heine et al. 1994). The LUBT reflects 
the time interval between the ingestion of the isotope and the subsequent rise of 13CO2:12CO2 
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in breath (Wutzke et al. 1997). Heine et al. (1995) concluded that the glycosyl 13C-ureide 
breath test reflected intestinal transit time, and that it acted as a specific marker for the action 
of colonic microbial flora (Heine et al. 1995). Previous studies have compared the LUBT with 
the H2BT in man (Wutzke et al. 1997) and horses (Sutton et al. 2000) and found the LUBT to 
be both more sensitive and more specific for OCTT measurement. Lactose 13C-ureide is 
synthesised by the acid-catalysed condensation of lactose and urea (Morrison et al. 2000). 
The lactose moiety may be cleaved in the small intestine to yield galactose and glucose 13C-
ureide, but the glucose-urea bond itself cannot be cleaved by intestinal brush border enzymes 
(Ruemmele et al. 1997). Rather, the bond is cleaved by intestinal microflora in ruminants 
(Merry et al. 1982), humans (Heine et al. 1994) and also horses (Sutton et al. 2000). 
Excellent correlation was reported between the LUBT and scintigraphy in humans (Wutzke et 
al. 1997; Geypens et al. 1999). Using the LUBT a good repeatability was found within 
individuals, and daily dietary variations had little effect on test results (Heine et al. 1995). In 
horses the LUBT was found to be a superior test to the H2BT in terms of both sensitivity and 
repeatability (Sutton et al. 2000; Sutton 2003). In vitro studies in the horse have also indicated 
that the cleavage of the glucose 13C-ureide moiety and subsequent hydrolysis of 13C-urea is 
relatively restricted to the large intestinal flora. Hence the 13C-LUBT should provide a 
relatively specific indicator of oro-cacal transit in the healthy horse (Sutton 2003). Hence, it 
was elected to use the LUBT for assessment of the effects of the different pharmacological 
compounds on OCTT in this study. 
 
2.4.4 Factors influencing Oro-Caecal Transit Time 
Dehydration has been shown to delay gastric emptying but has no significant influence on 
OCTT and intestinal motility in humans (van Nieuwenhoven et al. 2000). 
OCTT is determined by gastric emptying and small intestinal transit as well as by ileal 
emptying effects. Constipation is therefore a factor that delays OCTT (Geypens 2000). 
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In a human study, mouth-to-anus transit time, assessed by radio-opaque markers, showed no 
difference in age (Metcalf et al. 1987), whereas gastric, small intestinal and colon transit time 
studied by scintigraphy were found to be influenced by age and gender, with women having a 
slower gastric transit time (Graff et al. (2001). They further observed an acceleration of 
gastric emptying and small intestinal transit time with aging (Graff et al. 2001). The female 
menstrual cycle was not implicated in a study (Degen and Phillips 1996), gender bias was 
detailed elsewhere, where men had a shorter transit time for the whole colon (Metcalf et al. 
1987; Degen et al. 1996). 
 
2.4.5 Advantages 
As a stable non-radioactive isotope is used, there are no radiation hazards as is potentially the 
case with the use of radioactive isotopes (Halliday et al. 1982; Koletzko et al. 1997; 
Romagnuolo et al. 2002). The stable isotope breath tests are also easy to perform, painless for 
the patient and different breath tests can be performed simultaneously (Koletzko et al. 1997). 
Exhaled breath can easily be collected and respiratory mask measurements produced good 
results in veterinary medicine, as tested in swine (McKirnan et al. 1986) and ponies (Orr et al. 
1975). 
Only tracer amounts of substrate are necessary (Koletzko et al. 1997; Stellaard et al. 1998), or 
substrates that are naturally enriched with 13C in the presence of a low background 13C diet 
(Jonderko et al. 2005). Substrates are usually given orally (Rating and Langhans 1997) and 
breath samples can be stored at room temperature for up to eleven weeks (Schoeller et al. 
1977). Therefore this test has scientific and clinical value particularly in neonates, children, 
young adults and in pregnant women (Halliday et al. 1982; Koletzko et al. 1997) and for 
repeated testing (Koletzko et al. 1997; Rating et al. 1997; Swart and van den Berg 1998). 
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2.4.6 Disadvantages 
The main disadvantage is the natural background level of environmental 13C, against which 
estimation of isotope label must be made (Halliday et al. 1982; Koletzko et al. 1997; 
Romagnuolo et al. 2002). This background is approximately 1.1% in the case of 13C (Halliday 
et al. 1982; Koletzko et al. 1997) and depends on the composition of C3 and C4 plant material 
(Stellaard et al. 1998), as well as geographical situation and nutrition (Koletzko et al. 1997). 
There is also the high cost of the isotope-labelled substance, as well as the necessity for high-
technology measurement equipments (Halliday et al. 1982; Wutzke et al. 1997). An infrared 
spectroscopic technique has been developed to exchange the costly isotope ratio mass 
spectrometer, but a lower sensitivity and large sample volumes (Savarino et al. 1999) as well 
as the impossibility of automatic analysis of high sample numbers make this equipment only 
interesting for small gastroenterological centres (Savarino et al. 1999; Romagnuolo et al. 
2002). 
A further disadvantage of stable isotope breath tests is that any breath test has the same 
assumption of a substrate being metabolised to 13CO2, after intake of the 13C tracer. An 
increase of 13CO2 above baseline level is said to provide an indirect measurement of the 
function investigated (Rating et al. 1997). For this to be true, the metabolic or physiological 
function being studied must be the major rate-limiting step in the exhalation of 13CO2 rather 
than a combination of metabolic determinants (Swart et al. 1998). This might not be the case 
in diseased animals (Rating et al. 1997; Wyse et al. 2004). Since only the end product 13CO2 
is measured, there is no information on all the pools and fluxes through which the labelled 
substrate and its metabolites have to pass (Rating et al. 1997). 
Another disadvantage is that changes in the basal exhalation of 13CO2 during the test will have 
an impact on the breath test calculation. Moreover, the basal metabolic rate (BMR) and the 
actual endogenous CO2 production, which in most instances is unknown, is required for an 
exact calculation of percentage recovery of the specific stable isotope over time (Rating et al. 
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1997). In many clinical centres for humans, the BMR is now estimated indirectly, and allows 
more accurate assessment of total exhaled recovery of the ingested 13C-isotope to be made. 
Routine estimation of BMR is not yet available in horses, and so information on the 
percentage digestion and metablism of 13C-compounds in this species is less accurate. 
The hydrogen breath test that has been reported for assessment of OCTT in both humans and 
animals also has some disadvantages. Although Murphy et al. (1998) had satisfactory 
reproducibility in their analysis of duplicate samples (Murphy et al. 1998), it has been 
reported that the earlier used lactulose hydrogen breath test was poorly reproducible within 
(La Brooy et al. 1983; Ladas et al. 1989) or between subjects studied (La Brooy et al. 1983) 
and sedated cats (Sparkes et al. 1996). The overestimation of OCTT that occurs by the use of 
the hydrogen lactulose breath test, if the mean hydrogen concentration is within 15 ppm, can 
be reduced by a mean value of 10 min if a hydrogen threshold increment of 5 ppm is chosen 
to represent the arrival of the test meal at the caecum. This improves the correlation between 
the lactulose hydrogen breath test and scintigraphy to r = 0.90 for measurement of OCTT 
(Sciarretta et al. 1994). 
Pressman et al. (1987) used a 14C lactulose breath test to measure small intestinal transit time 
in man. They reported that besides the small within subject variation, there is only moderate 
accuracy for the test due to a delayed recovery of 14CO2 in breath. They also observed an 
increase of CO2 in subjects within 30 min. This is long before lactulose entered the colon and 
might be due to degradation of lactulose by aerobic bacteria in the small intestine (Pressman 
et al. 1987). 
A study comparing the lactulose hydrogen breath test with scintigraphy for measurement of 
OCTT, proved that although both tests correlated well, neither of them is accurate for the 
measurement of small intestine transit time. This is because lactulose accelerates small 
intestinal transit and slows gastric emptying and scintigraphy produces a wide range of OCTT 
measurements, making it difficult to assess delayed small intestinal transit (Miller et al. 
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1997). In scintigraphic assessment of OCTT, the arrival of 10% of the radioactive isotope in 
the caecum is generally taken to represent OCTT (Geypens et al. 1999; Geypens 2000; Van 
Den Driessche 2001), thus not allowing for prolonged retention of the majority of the 
radiolabelled meal in the small intestine. 
 
2.4.7 Disadvantages in veterinary medicine 
Despite these apparent drawbacks, breath tests using the 13C stable isotope of carbon have 
recently become more available in district hospitals and commercial laboratories (Swart et al. 
1998). 
Certain fundamental deficiency in the basic knowledge that is necessary for the analysis of 
breath tests make the use of them in veterinary medicine still difficult and therefore often 
confines them to research laboratories. The exact physiological origin of markers i.e. 
hydrogen, has yet to be established in animals, the effects of respiratory changes on the 
concentration of exhaled compounds, as well as the reference ranges for most of the markers 
for healthy and diseased animals have yet to be described (Wyse et al. 2004). 
 
2.4.8 Isotopes of carbon and their measurements 
An isotope is a chemical atom that contains the identical number of protons in its nucleus as 
an atom of its position in the periodical table of elements, but the number of neutrons in the 
nucleus is different. This leads to a different mass and different chemical, physical and 
biochemical behaviour (Koletzko et al. 1997). 
Carbon has eight isotopes, with six radioactive, unstable isotopes (9C, 10C, 11C, 14C, 15C, 16C) 
and two stable, non-radioactive 12C and 13C isotopes (Lefebvre 1985). 
In this study, 13C is used, having a natural abundance of approximately 1.1% (Svejcar et al. 
1993; Rating et al. 1997). This naturally occurring isotope can either be of (bio-) chemical or 
natural origin (Stellaard et al. 1998). Its use for clinical diagnostic and research is safe and 
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without any adverse side effects and is measured by isotope ratio mass spectrometry 
(Koletzko et al. 1997). 
The ratio of 13C:12C in a sample is always measured against a universal reference. This is 
usually the Pee Dee Belemnite limestone standard (PDB) in case of carbon originating 
substrates (Craig 1953; Craig 1957; Lefebvre 1985; Wolfe 1992; Stellaard et al. 1998). The 
results are expressed in δ13C, which is the ratio of these ratios (Lefebvre 1985): 
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The isotope content of grain and other primary plant material varies between different 
geographic areas (Nakamura et al. 1982). 
13C-labelled substrates can be produced either synthetically or obtained from naturally 
occurring substances that are isolated from animal or plant material (Swart et al. 1998). 
 
A comparison test between 15 participating laboratories in Europe revealed that all produced 
13C enrichment values within the specification of continuous flow isotope ratio mass 
spectrometers (Stellaard et al. 1998). 
 
2.4.9 Error rates 
An error that might be introduced into a 13CO2 breath test is due to the changes in the 
endogenous 13CO2:12CO2 ratio that varies due to substrate and dose. Small doses, as used in 
tracer studies, might only produce a small signal that could be drowned by fluctuations in the 
endogenous 13C:12C ratio. 
This error can be empirically corrected by measuring the change in endogenous breath 
13CO2:12CO2 by performing the breath test following the prescribed protocol, but in the 
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absence of labelled substrate. The measured changes in the 13CO2:12CO2 ratio relative to the 
baseline sample are then subtracted from the results of the breath test with labelled substrate 
for each point of time (Schoeller et al. 1984). 
 
2.4 10 Influence of exercise 
Although exercise other than extreme exertion does not influence gastrointestinal transit time 
itself in man (van Nieuwenhoven et al. 1999), ponies and donkeys (Pearson and Merritt 
1991), it leads to a decrease in dry matter digestibility as well as reduction in mean retention 
time (Pagan et al. 1998). A change in the mix of endogenous substrates that is oxidised for 
energy will change the source of substrate for energy metabolism, and is therefore likely to 
change the natural enrichment of expired CO2. This can result in an increase in background 
enrichment (Schoeller et al. 1977; Wolfe et al. 1984), influencing measurement of oro-caecal 
transit time (which depends on assessment of small increases in exhaled 13CO2). 
Heavy exercise, on the other hand, rapidly decreases the 13C:12C ratio of breath CO2 initially, 
before it then slowly increases (Schoeller et al. 1984). This may be explained by the 
withdrawal of carbohydrates from the bicarbonate pool during the transition from rest to 
exercise. Another reason might be the increased lipid utilisation that was not reflected in the 
respiratory exchange due to no equilibrium of gas exchange in the transition state. The 
decrease could also be due to a kinetic isotope effect that was expressed during the transition 
period when bicarbonate kinetics were not at equilibrium (Schoeller et al. 1984). 
 
2.4.11 CO2 production 
The carbon dioxide production rate (VCO2) at the time of a breath test is determined by the 
metabolic rate at that time. Since this rate is influenced by exercise, subjects should rest for 
the duration of breath tests (Swart et al. 1998) as CO2 production is required to calculate 
percentage 13C recovery, which provides the indirect measure of transit time. 
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A constant body pH throughout a 13C tracer study is important also, as the acid/base balance 
is an important factor affecting the bicarbonate elimination kinetics and therefore the breath 
CO2 (Leese et al. 1994). 
The actual CO2 production has to be known to calculate an accurate % 13C elimination (in the 
percentage of 13C administered) (Rating et al. 1997). It is preferential to measure this actual 
CO2 production, but if this can not be performed, the VCO2 can be calculated from the basal 
metabolic rate (BMR) (Amarri et al. 1998). 
In humans, use of an estimate of 9 mmol/kg per hour of endogenous CO2 production is 
recommended for calculations in any person, irrespective of body shape and age (Rating et al. 
1997). 
 
2.4.12 Influences on 13C enrichment 
Fat oxidation starts in humans after an eight hour fast. Because of the lower natural 13C 
enrichment of lipids compared to that of carbohydrates, the baseline 13CO2 exhalation will 
decrease when oxidation shifts from carbohydrates to lipids. This mechanism causes the 
13CO2 exhalation to drop below baseline during more prolonged breath test regimens (Rating 
et al. 1997) and correction must be made for this phenomenon. 
When a fasting subject receives carbohydrates, the low enrichment of expired CO2 that is 
caused by the oxidation of fat during fasting, will increase, as carbohydrates will be used for 
the physiologically favoured glucose oxidation (Wolfe et al. 1984). Ingestion of subsequent 
meals during a breath test period increases breath 13CO2 abundance due to a shift in substrate 
oxidation, affects the variability within subjects (Jones et al. 1985) and increases the OCTT 
(Priebe et al. 2004). 
Therefore, in order to avoid any metabolic disturbances or undue variability, it is 
recommended that the test subjects fast overnight before the test and throughout the test 
(Schoeller et al. 1977). 
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2.4.13 Test meal 
The validation of a stable isotope breath test requires the selection of a suitable test meal that 
should be low in natural background 13C (Boutton 1991). Furthermore a hay diet is more 
suitable, as diets containing grain influence heart rate, rectal temperature and could delay 
gastrointestinal transit time (Lopes et al. 2004). 
The composition of the test meal with respect to energy density and fat content is important as 
it influences gastric emptying and therefore the time when the substrate will be available for 
metabolic processes to be studied (Swart et al. 1998). 
The natural abundance of 13C in food is approximately 1.1% (Morrison et al. 2000), which 
reflects the enrichment or depletion of 13C relative to 12C due to isotope fractionation 
(Schoeller et al. 1980). 
The variation of natural abundance of 13C in food depends on the plant and the pathway used 
for photosynthesis. The Calvin-Benson or so called C3 pathway involves C3 plants such as 
beet root or potatoes, which utilise a three-carbon intermediate to fix atmospheric CO2 into 
plant material. C4 plants such as maize, sugarcane and related grasses use a four-carbon 
intermediate for this process. This is called the Hatch-Slack or C4 pathway (Hatch and Slack 
1970). C4 plants are significantly more enriched with 13C and therefore animals, which have 
ingested these plants will present a higher increase of 13C within their tissue (Halliday et al. 
1982). Tropical plants are high in C4 (Lefebvre 1985). 
Therefore test meals for stable isotope breath tests generally have a low level of C4 plant 
material unless the natural diet (and body reserves) of the test subject are high in 13C. 
Driessche (2001) reported that liquid test meals do not reveal any abnormalities in patients 
with gastrointestinal disorders and recommends only the use of solid test meals (Van Den 
Driessche 2001). Solid phase test meals allow a more physiological assessment to be made of 
genuine motility disorders that might not be apparent in the liquid phase. 
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2.5 CONTINUOUS FLOW ISOTOPE RATIO MASS SPECTROMETRY (CF-IRMS) 
2.5.1 Background 
Historically, mass spectrometers were mainly used for physical studies of terrestrial isotopes 
(Brenna et al. 1997), in chemistry research laboratories and petroleum and pharmaceutical 
industries (Matern and Magera 2001). 
In this study, a continuous-flow isotope ratio mass spectrometer (CF-IRMS) was used. These 
high-precision spectrometers have a gas chromatograph interfaced with an isotope ratio mass 
spectrometer, which increases sensitivity and speed of analysis (Brenna et al. 1997). 
CF-IRMS are robust and simple, with staff having basic chromatography experience being 
able to operate it with ease (Preston and McMillan 1988). 
 
2.5.2 Principle of a CF-IRMS 
Once the sample is introduced into a spectrometer, the sample containers are loaded into an 
auto sampler, into which a double, concentric needle is inserted. The needle is flushed with 
helium before insertion and the carrier flow of helium is further used to flush out the sample 
gas from the container. After passing through a drying tube, containing MgClO4 for removing 
water vapour, the gas reaches a packed column gas chromatograph, in which CO2 is separated 
from other gases. The purified CO2 pulses to the mass spectrometer inlet (Prosser et al. 1991), 
where the target isotope of interest is ionised and bombarded by electrons (Bier and Matthews 
1982; Matern et al. 2001), so that some molecular ions become positively charged (Wolfe 
1992). These ions reach the mass spectrometer and the magnet inside deflects them according 
to their mass to charge (m/z) ratio (Klein and Klein 1985; Wolfe 1992; Van Den Driessche 
2001; Matern et al. 2001). The masses 44, 45 and 46 (12C16O2, 13C16O18O and 12C16O18O, 
respectively) are collected by a triple collector (Prosser et al. 1991; Wolfe 1992; Van Den 
Driessche 2001), so that both the 13C:12C and 18O:16O ratios can be calculated for the CO2 
(Craig 1957). 
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Jonderko et al. (2005) have investigated the recently developed and cheaper non-dispersive 
infrared spectrometry (NDIRS) by analysing breath samples (Jonderko et al. 2005). Braden et 
al. (1999) have compared the NDIRS with the isotope ratio mass spectrometry for analysis of 
13C:12C ratio and found that both spectrometers produced excellent and comparable results. 
This new spectrometer might in future be a low-cost and easy-to-operate alternative (Braden 
et al. 1999). 
 
 
2.6 LACTOSE 13C-UREIDE BREATH TEST FOR ORO-CAECAL TRANSIT TIME 
MEASUREMENT 
2.6.1 Background 
The induced lactose 13C-ureide breath test (LUBT) has been developed by Heine (Heine et al. 
1995) and validated against the predicate method of enterocolonic scintigraphy for the 
measurement of OCTT in man (Wutzke et al. 1998; Geypens et al. 1999). Geypens et al. 
(1999; 2000) reported an excellent correlation between the LUBT and scintigraphy for OCTT 
measurement (292 ± 58 min and 283 ± 53 min; P = 0.0001), and concluded that the breath test 
was a valid alternative to scintigraphy for OCTT measurement (Geypens et al. 1999; Geypens 
2000). Wutzke et al. (1997) also compared the LUBT to the older lactulose hydrogen breath 
test and reported that the former had both greater sensitivity and specificity for OCTT 
measurement (Wutzke et al. 1997). In human gastroenterology the LUBT was also 
investigated in infants that were not yet weaned (Van Den Driessche et al. 2000; Van Den 
Driessche 2001; Christian et al. 2002a). 
 
2.6.2 Principle 
The basis of a breath test for OCTT measurement is the ingestion of a non-absorbable 
carbohydrate, which gets fermented by microbes in the caecum and then found as an increase 
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in exhaled hydrogen (Wyse et al. 2004). Lactose ureide is an ideal tracer for the evaluation of 
OCTT, as the sugar-urea bond is inert to intestinal enzymes and also has no osmotic effect on 
gut motility (Ruemmele et al. 1997). Roberts (1975) reported horses older than three years 
having a lactase enzyme deficiency and therefore being lactose intolerant (Roberts 1975), 
which makes them suitable for the LUBT. 
Lactose 13C-ureide is a tasteless (Geypens et al. 1999) glycosyl ureide that is synthesised by 
the acid-catalysed condensation of lactose and urea (Morrison et al. 2000). 
 
 
 
 
Figure 2.6.2.1: 4-O-(ß-D-galactopyranosyl)- ß- D-glucopyranosyl ureide (LACTOSE 
UREIDE), * denotes the position of 13C enrichment (Morrison et al. 2003) 
 
The underlying principle of the LUBT is the enzymatic splitting of the stable isotope labelled 
lactose-ureide (LU) by intestinal microbes to NH3 and 13CO2. The latter can be measured in 
exhaled breath samples when the isotope reaches the caecum (Mohr et al. 1999). 
Ingestion of LU is followed by bacterial cleavage of the glycosyl-ureide bond in the large 
intestine (Heine et al. 1995; Geypens 2000), exclusively by bacterium Clostridium innocuum 
(Wutzke et al. 1998; Mohr et al. 1999). Subsequent hydrolysis of the 13C-urea moiety results 
in the production of a detectable increase in 13C:12C output from the body bicarbonate pool. 
Hence, mass spectrometric analysis of the 13C:12C ratio in expiratory breath after ingestion of 
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the labelled test meal provides an indirect measure of the rate of OCTT (Heine et al. 1995; 
Geypens 2000). This test recently has been validated in vitro for the measurement of equine 
OCTT and used in vivo to provide estimation of small intestinal transit times (Sutton 2003). 
 
Premedication with unlabelled LU the day prior to the test leads to a higher and steeper 13CO2 
enrichment during the test (Wutzke et al. 1997; Geypens 2000; Morrison et al. 2003). This is 
due to the induction of microbial enzyme activity (Wutzke et al. 1998). Without induction on 
the day prior to the test with unlabelled LU, a significant percentage of test subjects will not 
show sufficient increase of 13CO2 in breath to allow unambiguous interpretation of the LUBT 
(Geypens 2000). The metabolism of the tracer molecule is much slower in the absence of 
induction (Geypens 2000; Van Den Driessche 2001). 
However, in humans, premedication of 1g unlabelled LU two hours prior to the labelled test 
meal resulted in a shortening of transit time to 2.5 hours due to enzymatic activity (Heine et 
al. 1994). Morrison et al. (2003) also observed a shortening of OCTT after premedication of 
unlabelled substrate in some subjects (Morrison et al. 2003). 
The principle of the LUBT for measurement of OCTT is shown in Figure 2.6.2.2: 
Ingestion of 
lactose 13C-
ureide
13C-urea
Bacterial cleavage of sugar-
ureide bond in caecum
13C:12C ratio in breath Mass spectrometric 
analysis
13CO2
Bicarbonate 
pool
 
Figure 2.6.2.2: The principle of the LUBT for measurement of OCTT (Sutton 2003) 
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2.6.3 Disadvantages of LUBT 
The LUBT is not suitable for use in infants prior to weaning, as they do not have the 
necessary bacterium Clostridium innocuum to split the glycosyl bond. Small intestinal 
overgrowth also limits the application of the LUBT (Van Den Driessche et al. 2000; Van Den 
Driessche 2001), as a positive breath signal would occur earlier than expected (Ruemmele et 
al. 1997). 
The expense of the IRMS-analysis, high cost of the lactose-[13C]ureide and the LU 
pretreatment for the induction of enzyme activity are among the disadvantages of the LUBT 
(Wutzke et al. 1997). 
Variability between individuals evaluated for OCTT was described, attributed to the 
differences in the metabolic activity of the colonic microflora (Jackson et al. 1999). 
 
In this study, the effects of imidocarb dipropionate on equine OCTT, and the relative effects 
of atropine or glycopyrrolate premedication were quantified using stable isotope breath test 
technology. Pharmacological effects on OCTT were studied using the lactose 13C-ureide 
breath tests (Geypens et al. 1999; Sutton 2003). The primary study objective was to determine 
the optimum dosing strategy for equine babesiosis in order to minimise the gastrointestinal 
complications associated with treatment. 
 
Semi-quantitative studies of gastrointestinal motility using transabdominal ultrasonography 
have suggested that the effect of imidocarb on gut motility is best ameliorated by 
premedication with glycopyrrolate (Donnellan et al. 2003a). Since non-invasive quantitative 
stable isotope tests have now been validated for the measurement of equine OCTT, it is aimed 
in this study to quantify the effects of treatment modalities on this specific parameter of 
intestinal transit. The objectives of this study are as follows: 
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- to improve knowledge of the specific effects of imidocarb treatment on oro-caecal 
transit time 
 
- to quantify the effects of premedication with atropine or glycopyrrolate 
 
- to develop/validate a clinical protocol for treatment of babesiosis that results in 
minimal gastrointestinal complications 
 
 
2.7 HYPOTHESIS 
• When administered without premedication imidocarb dipropionate at 2.4 mg/kg IM 
will result in clinical signs of abdominal pain and colic in a proportion of horses. 
 
• Treatment with imidocarb dipropionate at 2.4 mg/kg IM will result in increased small 
intestinal motility, and a reduction in oro-caecal transit time as demonstrated by the 
lactose 13C-ureide breath test. 
 
• As atropine has been proven previously to decrease equine small intestinal motility, 
premedication of horses with atropine or glycopyrrolate will reduce the changes in 
intestinal transit rate caused by imidocarb dipropionate. 
 
• Premedication with atropine or glycopyrrolate will reduce the incidence of clinical 
side effects seen with imidocarb treatment alone. 
 
• Premedication with atropine will result in a greater delay in small intestinal transit 
than seen with both the control and glycopyrrolate premedication groups.
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CHAPTER 3 
GENERAL MATERIALS AND METHODS 
 
3.1 STUDY DESIGN 
The preliminary part of the study entailed measurements of basal 13C:12C expiratory ratio in the 
study animals under experimental conditions, to ensure that this parameter remains constant. 
The method of breath collection and analysis was performed as described below. This part of 
the study trials also ensured that the test meal and stable isotope substrate was palatable to all 
the study animals. 
 
The study was thereafter divided into a randomised treatment trial. The effects on gut motility 
of three drug therapies (imidocarb dipropionate 2.4 mg/kg IM with saline IV; imidocarb 
dipropionate 2.4 mg/kg IM with atropine 0.035 mg/kg IV; imidocarb dipropionate 2.4 mg/kg 
IM with glycopyrrolate 0.0025 mg/kg IV) were tested against a saline control (saline IM with 
saline IV). The following drugs were used: imidocarb dipropionate (Forray 65®, Schering-
Plough (Pty) Ltd, Isando, R.S.A.), atropine sulphate (Atropine 10®, Bayer Animal Health 
Division, Isando, R.S.A.), glycopyrrolate (Robinul®, Pharmacare Limited, Port Elizabeth, 
R.S.A.) and saline (Sodium Chloride 0.9%, Renalcare Service (Pty) Ltd, Midrand, R.S.A.). 
The intramuscular injection followed the intravenous injection immediately in each 
individual. Throughout the trial the same batches of drugs were used. 
 
The relative effects of the compounds on oro-caecal transit time (OCTT) were measured in 
six healthy horses using the induced lactose 13C-ureide breath test (LUBT). Each horse 
received one treatment per week in randomised order, with a one-week wash out period 
between different drug therapies. All subjective clinical variables were assessed by the 
primary investigator. 
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Since factors such as dietary composition, volume and consistency, exercise and 
physiological stress are known to affect equine gastrointestinal motility, all attempts were 
made to minimise these variables. Temporal effects on gut function were eliminated by the 
randomised nature of the study design. 
 
 
3.2 STUDY ANIMALS 
The study was performed on six healthy adult equidae (one Thoroughbred gelding, three 
Thoroughbred mares, one Basuto pony gelding and mare each), selected from the Equine 
Research Centre herd, Faculty of Veterinary Science, Onderstepoort, South Africa. Their 
range of age was four to 13 years (mean 8.2) and their body weight ranging from 339 to 545 
kg (mean 460 kg). 
Four horses and three ponies were used for the basal trial, however, one pony was later 
withdrawn from the study after consistently refusing the test meal. 
 
3.2.1 Animal selection 
The selected animals were in good body condition and had no recent history of colic. Five 
weeks prior to the trial, blood samples were collected by jugular vein puncture into potassium 
ethylenediaminetetraacetic acid (EDTA) and serum tubes (Vacutainer®, Becton Dickenson, 
SA Scientific, Randburg, R.S.A.). Diagnostic blood tests were done, consisting of total blood 
cell count, examination for blood parasites and biochemical analysis. The latter included total 
serum protein, albumin, globulin, albumin-globulin ratio, aspartate aminotransferase, gamma 
glutaryltransferase, urea and creatinine serum concentrations. The blood parameters were 
evaluated at the Section of Pathology, Department of Medicine, Faculty of Veterinary 
Science, Onderstepoort, South Africa. 
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A general physical examination and faecal examination for Nematode egg count and Cestode 
egg recovery was performed. The Department of Veterinary Tropical Diseases, Faculty of 
Veterinary Science, Onderstepoort, South Africa carried out the helminthological evaluation. 
One horse tested positive and therefore was administered an Ivermectin-Praziquantel 
anthelmintic (Equimax® oral paste, Virbac (Pty) Ltd, Halfway House, R.S.A.) one month 
prior to the trial. 
All other subjects were dewormed with Fenbendazole (Panacur®, Intervet (Pty) Ltd, Isando, 
R.S.A.) in February 2005 and showed negative helminthological results. 
 
3.2.2 Management of test subjects 
All subjects were brought in from pastures and stabled in individual loose boxes two weeks 
prior to the trial at the stables of the Equine Research Centre, Faculty of Veterinary Science, 
Onderstepoort, South Africa. They were bedded on wooden shavings and were fed hay and 
lucerne twice daily. Two weeks prior to the trial as well as from Friday to Sunday of each 
week during the study, subjects were allowed on the pasture during day time. This was done 
to reduce stress and the risk of impaction colic. Any exercise for the period of the study was 
otherwise restricted to minimise metabolic influences on gastrointestinal motility. 
One horse presented colic signs, due to an impaction of the pelvic flexure, once between the 
test days. This horse was therefore stabled for a period of 24 hours at the Equine Clinic of the 
Faculty of Veterinary Science, Onderstepoort, South Africa and treated with a two-hourly 
drenching using Epsom salts initially and then a technical oil - water mixture. 
All subjects were stabled and fasted 14 hours prior to the test as this eliminates or reduces 
baseline shifts in 13C abundance (Schoeller et al. 1980). 
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3.2.4 Ethics and welfare 
The procedures detailed in this thesis were approved in advance by the Animal Use and Care 
Committee and the Research Committee, Faculty of Veterinary Science, Onderstepoort, South 
Africa. 
The method used for assessment of gastrointestinal motility in this study was entirely non-
invasive and generally extremely well tolerated by the horses. Collection of each breath 
sample took approximately two minutes, during which time the horse breathed through the 
Aeromask® (Trudell Medical International, Ontario, Canada). The stable isotopes are safe and 
have been used extensively in human and veterinary medicine without detrimental effect. 
Although some studies have indicated that imidocarb dipropionate has dose-dependent 
hepato- and nephrotoxicity in a number of species, a recent study concluded that even 
sterilisation protocol doses of imidocarb (4 mg/kg IM every 72 h) had minimal effect on 
function of either of these organs (Meyer 2002; Meyer et al. 2005). A considerably lower 
dose of imidocarb was required in this study compared to the other study (Meyer 2002; Meyer 
et al. 2005). 
 
 
3.3 TEST MEAL 
The test meal consisted of 150g oats, 100g wheat bran and 200ml water for horses and 75g 
oats, 50g wheat bran and 100ml water for ponies. This contained 2.895 MJ for horses and 
1.448 MJ for ponies, based on the digestible energy (D.E.) contents of 12.1 and 10.8 MJ/kg 
dry matter for oats and wheat bran, respectively (Frape 2004). Lactose 13C-ureide (Bell 
College of Technology, Hamilton, Scotland) (2.7 mg/kg bwt β-lactosyl 13C-ureide dihydrate) 
was incorporated into egg white, which was cooked in a microwave for approximately 60 
seconds until firm, then homogenised and thoroughly mixed into the test meal. 
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3.3.1 Calculation of the dose 
The required dose is usually between two to 20 times the minimum detectable dose, which 
depends on the occurring fluctuation and is at least twice the standard deviation. This would 
be 1.4 per mil as the usually fluctuation occurs within the standard deviation of 0.72 per mil 
(Schoeller et al. 1977). Previous studies recommend an ideal dose of labelled lactose ureide 
(LU) of 3 mg/kg bwt and 15 mg/kg bwt for the unlabelled LU for the LUBT in horses (Sutton 
2003). In human studies the dose of unlabelled LU varies between 500 mg for children (Van 
Den Driessche 2001) and 1 g for adult (Wutzke et al. 1998; Geypens et al. 1999), and 250 mg 
for children (Van Den Driessche 2001) and from 500 mg (Geypens et al. 1999) to 1 g 
(Wutzke et al. 1998) of 13C-LU for adult. 
In this study 30 mg/kg bwt of unlabelled LU were fed 18 hours before the test to induce 
enzymatic activity of the colonic bacteria. The labelled LU was fed at a dose of 2.7 mg/kg 
bwt. 
 
 
3.4 LACTOSE 13C-UREIDE BREATH TEST 
The induced lactose 13C-ureide breath test (LUBT) was used to measure OCTT and further 
specific parameters of small intestinal transit rate. 
T1/2 indicates the time needed for half of the marker molecule to be emptied from the 
stomach, transported to the caecum, metabolised by bacteria, taken up in the blood 
bicarbonate pool and excreted in breath as carbon dioxide. This parameter thus describes 
more than oro-caecal transit of the head of the chyme (Geypens 2000). 
 
3.4.1 Breath test protocol 
The horses were fasted for 14 hours prior to the tests to ensure an empty stomach. Attempts 
were made to minimise all possible external/environmental factors on intestinal transit rates 
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and alterations in VCO2 by fasting and resting animals before and during the trial. Two basal 
breath samples were collected 60 and 0 min before test meal ingestion to estimate the basal 
13C production. Thereafter, samples were taken in duplicate at 30 to 60 min intervals for 12 
hours. 
The time at which the test meal was given, was determined as 0 min. 
Immediately after the test meal had been eaten, each horse was injected with the selected drug 
combination. One intravenous and one intramuscular injection was given in a blinded manner 
(saline IV/saline IM; glycopyrrolate IV/imidocarb IM; atropine IV/imidocarb IM; or saline 
IV/imidocarb IM). Breath sample collection was then continued at 30 to 60 min intervals for 
12 hours. 
 
For the duration of the study period subjects were fed a constant diet of lucerne/teff hay 
without concentrates, and allowed access to grazing. On the day before each breath test was to 
be performed the horses were stabled to minimise environmental influences on gut function. 
The subjects were stabled and maintained at rest for the duration of each test to minimise 
fluctuations in CO2 production (VCO2) and intestinal motility. Access to food and water was 
not allowed for the first ten hours of each study. Every horse was tested weekly for four 
weeks, to measure the relative effects of treatment on OCTT. Three horses were sampled at 
each trial day. Tuesdays and Wednesdays were designated as weekly data collection days. On 
the day before the test, horses were pre-fed with unlabelled LU to maximise bacterial 
enzymatic activity. 
 
3.4.2 Collection of breath samples 
Expiratory samples were collected using a previously validated technique (Sutton 2003). Prior 
to each sampling point a modified Aeromask® (Trudell Medical International, Ontario, 
Canada) was fitted to each horse’s muzzle, and the horse allowed to breathe through the 
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inspiratory and expiratory valves of the mask. As resting horses have irregular breathing 
patterns with variable tidal volumes and flow rates (Slocombe et al. 1992) and a lower 
respiratory frequency when using a mask (Evans and Rose 1988), each horse was allowed to 
in- and exhale for several times before the collection bag (QuinTron®, QuinTron Instrument 
Company, Wisconsin, USA) was attached. In this way we made sure that dead space of the 
Aeromask® was filled with breath CO2. Expiratory samples were collected by attaching the 
QuinTron® bag with one-way valve to the expiratory section of the mask. This collection 
technique, which took approximetly two minutes to perform, is found not to disturb the 
horse’s breathing (Orr et al. 1975). The Aeromask® was removed between sampling events. 
Breath samples were then, as described (Schoeller and Klein 1978), transferred via 20 ml 
syringes and attached three-way stop cocks (both B. Braun Medical (PTY Ltd, Randburg, 
R.S.A.) in duplicate to 10 ml Vacutainers® (Becton Dickenson, Lincoln Park, NJ, USA) and 
stored at room temperature prior to analysis. Experiments have shown that samples stored in 
this way remain stable for at least eleven weeks (Schoeller et al. 1978). 
 
Figure 3.4.2.1: Equipment for duplicate breath collection. 
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 Figure 3.4.2.2: Horse with Aeromask® and attached QuinTron® bag for breath 
collection. 
 
 
 
 
3.5 MEASUREMENT OF 13C:12C RATIO 
Sample analysis was originally performed in South Africa by the stable light isotope unit of 
the Department of Archaeology, University of Cape Town. Vacutainers® containing the 
samples for analysis were sent in batches to the University of Cape Town by courier service. 
On analysis of the first samples, problems were evident in that no breath was found captured 
in the Vacutainer®. We then sent further samples to the department at Cape Town University 
via the land route as it was suggested that the breath might leak out during transport in an 
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airplane. After the same problem recurred, it was then decided to send duplicates of all 
samples for examination to Dr. Thomas Preston, Senior Lecturer in Isotope Biochemistry, 
Scottish Universities Environmental Research Centre, University of Glasgow, Scotland. All 
samples were successfully analysed without further incident. 
 
Samples are usually measured as 13C:12C ratio against the Pee Dee Belemnite limestone 
(PDB) standard (Craig 1953; Craig 1957; Wolfe 1992). This standard refers to a Creataceous 
belemnite from the Pee Dee formation in South Carolina (Craig 1957), with an actual isotopic 
ratio of 0.011273 (Craig 1953; Wolfe 1992). The 13C enrichment is expressed as δPDB13C “per 
mil” (o/oo), as defined by Craig (1953). 
The 13C:12C content of each sample was measured relative to the international Pee Dee 
Belemnite limestone fossil standard (δ13CPDB) by continuous flow isotope ratio mass 
spectrometry (CF-IRMS) using following equation that shows the relative difference in the 
ratio 13C:12C between the sample and the standard parts per thousand: 
 
 1000 ∗  = )( 
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Where 13C:12CPDB and 13C:12Csample are the ratio of the standard and sample respectively. 
 
Reference gases are analysed at the beginning of each batch run and every five to ten samples 
thereafter. Thereby, an amount of CO2 of known isotopic composition and partial pressure is 
injected and analysed (Prosser et al. 1991). The CF-IRMS can measure with a precision of 
~1.0 per mil for 13C, with 220 samples and standards being automatically analysed in ~18 
hours (Prosser et al. 1991). 
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Before and after each horse’s samples of a trial day were run, an accuracy check was 
performed with the CF-IRMS automatically. 
 
The natural abundance of 13C in an animal reflects the natural abundance of 13C in its diet. 
Most biological specimens have a smaller content of 13C than PDB, resulting in breath test 
samples having negative values (Lefebvre 1985; Klein et al. 1985). This indicates that the 
sample is “lighter”, i.e. contains less 13C than the standard gas. The values represent relative 
abundance variations only (Craig 1953). 
 
According to recommendations (Slater et al. 2001), S.I. notation has been used and therefore 
δPDB13C was converted into the S.I. units of atom % 13C (AP13C), using the following 
equation: 
    
 AP13C =
RPDB*)1)1000//((11
100
++ δ  (Slater et al. 2001) 
    
 
Where δ is measured δPDB13C and RPDB is the isotope ratio of PDB = 0.0112372. 
Although the S.I. unit atom % excess or mol% excess for enrichment are recommended units 
for tracer studies (Slater et al. 2001), parts per million (ppm) excess were used here, as very 
small levels of enrichment were among our results. 
This was calculated using the formula: 
 
 ppm excess13C = ((atom %)E-(atom %)B) x 104 (Christian et al. 2002b; Sutton 2003) 
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Where (atom %)E is the measured abundance of the enriched breath sample after the test meal, 
and (atom %)B is the average measured abundance of the baseline breath sample, before 
ingestion of the isotope tracer. 
 
VCO2 is needed for the estimation of percentage dose recovery per hour (PDR/h) and there 
are differences in VCO2 between horses and ponies. Measurement of absolute VCO2 of each 
animal used in this study was not practical. Therefore two formulae were used for estimation 
of VCO2. Orr et al. (1975) proposed a formula, based on measurements in resting, non 
anaesthetised ponies of mean mass 147 kg, where mean resting VCO2 was found to be 
equivalent to 0.156 (SE ± 0.010) l/min/m2, where pony body surface area = (10.5 x (bwt (kg) 
x 1000)2/3) / 10000 (Orr et al. 1975). VCO2 in horses was found to be 2.84 (SD ± 0.42) 
ml/kg/min in a study comparing ventilation and gas exchanges in horses and cows (Gallivan 
et al. 1989). 
 
If subjects are fed a loading dose of unlabelled substrate, an absolute baseline correction can 
be calculated, using the following formula (Schoeller et al. 1980): 
 
Excess/deficit per 13C (mM) = 31313 10**)(
substrate unlabeled mg
2 −− nRPDBMCOLD δδ  
      
Where M is molecular weight, n is number of labelled carbon positions and RPDB is Pee Dee 
Belemnite limestone standard of 0.011273 
If test meal contains different components, it is difficult to calculate the baseline correction 
and the empirical approach can be used. Therefore a baseline trial can be done, which follows 
the same protocol as the study except without feeding a labelled substrate. The 13C abundance 
for each time point is then subtracted from the one when the study with labelled substrate is 
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performed. A larger dose of labelled substrate will be needed as the empirical approach 
increases uncertainty of 13C breath test (Schoeller et al. 1980). 
 
Irving multiplied baseline samples by their percentage CO2 to obtain an estimate of CO2 
output, which was normalised using the subject’s weight or body surface CO2 output. For the 
entire six hours kinetic measurement was obtained by averaging the hourly values (Irving et 
al. 1983). 
Incremental changes in 13C abundance over baseline values were obtained by subtracting the 
mean of Delta per mil vs. PDB at -30 and -15 min from the subsequent Delta per mil vs. PDB 
values (Irving et al. 1983). This is the approach we used in hour study. 
 
Finally the data were expressed as percentage dose recovery (PDR) of the labelled substrate 
per hour. The % administered isotope recovered as CO2 was calculated with the following 
equation: 
 
 PDR/h = 100
enrichment dose / MW)dose (mg
enrichment CbreathVCO 132 ×⎥⎦
⎤⎢⎣
⎡
××
×
n
 (Morrison et al. 2003) 
 
Where VCO2 is the CO2 production rate, breath 13C enrichment is the 13C enrichment of 
breath of breath over baseline (ppm excess), mg dose is the amount of substrate administered 
(mg), MW is the molecular weight of substrate, dose enrichment is the 13C enrichment of 
substrate (ppm13C), and n is the number of isotopically labelled atoms in the substrate 
molecule. 
 
Cumulative PDR (PDRcum) for the breath test was calculated by integrating the PDR values 
over the period of the test. PDRcum for a given time is the PDRcum of the previous point of 
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time plus the mean PDR of the time interval. This is multiplied by this time interval and is 
expressed in hours (Geypens 2000). 
PDRcum for the breath test was calculated using the following equation: 
 
 Cum PDR = [(PDRt + PDRt-1) x ∆t (h)/2] + cum PDRt-1 (Geypens 2000) 
 
By using the LUBT, OCTT has been defined as the point of time at which 3% of the 
cumulative dose recovery of the administered isotope has occurred in the exhaled breath. This 
was specifically calculated by Gammainv function using Microsoft Office® Excel 2003 
(Microsoft Corporation, Redmond, USA) (Sutton 2003). 
 
OCTT = Gammainv (0.03; b + 1; 1/c) 
 
 
3.6 MODELLING AND STATISTICAL ANALYSIS 
As recommended by Elashoff et al. (1982) curves were fitted separately for each individual 
subject using nonlinear least square regression (Elashoff et al. 1982). 
The results of the breath tests were expressed as percentage (%) dose 13C-isotope recovered 
against time (PDR/hour). The 13CO2 excretion curve was modelled using a non-linear power 
regression formula, developed for human stable isotope gastrointestinal data (Ghoos et al. 
1993): 
  y = atbe-ct 
 
Where y is the percentage of the 13C dose recovered in breath per hour, t is the time in hours 
and a, b and c are regression constants. The variable a is the scaling factor related to the 
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amplitude of the peak, b relates to the ascending slope, c to the decay slope and d is a delay 
factor (Morrison et al. 2003). 
To facilitate the fitting of multiple peaks, a further variable d was used. The equation that 
describes a peak now becomes (Morrison et al. 1998): 
 
  y = a(t-d)be-c(t-d) 
 
The best model to the actual data was fitted using a least mean squares approach, using the 
Solver function of Microsoft Office® Excel 2003 (Microsoft Corporation, Redmond, USA). 
 
Pattern of 13CO2 recovery from equine bicarbonate pool is multiphase in nature, with more 
than one rate-limiting step (Sutton 2003). 
 
Further t1/2 is derived from this formula, which indicates the time to recovery of 50% of the 
total cumulative dose recovered. As this can be calculated from the integral of the model, the 
Gammainv function in Microsoft Office® Excel 2003 (Microsoft Corporation, Redmond, 
USA) was used: 
 
 t1/2 = Gammainv (0.5; b+1; 1/c) (Sutton 2003) 
 
Tlag is equivalent to that time at which recovery of 13C label becomes maximal rate in exhaled 
breath. It is calculated as following: 
 
 tlag = b/c (Sutton 2003) 
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OCTT, tmax and PDR could be calculated from the fitted curve. OCTT was taken as that point 
of time at which a cumulative 3% of total isotope recovery was achieved. Tmax was defined as 
the time from ingestion of the substrate to the time of maximal breath enrichment and was 
calculated by the following equation: 
 
  tmax d+=
c
b  (Morrison et al. 2003) 
 
Mean quantitative data was therefore gained in each study, allowing assessment of the relative 
effects of the different treatment strategies on OCTT. A linear model analysis of variance 
(ANOVA) was used to assess whether or not the different compounds cause a significant 
difference to OCTT as compared to each other and to the saline control tests. Paired t-tests 
with a confidence interval of 95% were also used to determine intra-individual significance of 
the different treatment groups. Linear model ANOVAs were performed using MinitabTM for 
Windows, release 13 (Minitab Inc., State College, PA, USA). The paired t-tests were 
performed using SigmaStat 3.11 for Windows (Systat Software, Inc., Richmond, CA, USA). 
ANOVA has greater statistical power to detect treatment effects than other methods (Vickers 
and Altman 2001). 
 
 
3.7 CLINICAL MONITORING 
Clinical recordings were made from each subject at one hour prior to isotope ingestion and 
then one, two, three, five, seven, nine, eleven and twelve hours thereafter and recorded in 
tabular form. Parameters to be recorded included mucous membrane colour, capillary refill 
time, heart and respiratory rate, temperature, intensity and frequency of intestinal borborygmi 
on the left dorsal, left ventral, right dorsal and right ventral quadrant, faecal output and 
consistency and presence or absence of signs consistent with abdominal pain (e.g. flank 
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watching, pawing ground, lying down). When signs of pain became marked, the horses were 
monitored closely over the entire period of discomfort. 
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CHAPTER 4 
CLINICAL CHANGES IN SIX HEALTHY HORSES FOLLOWING 
SPECIFIC BABESIOSIS TREATMENT 
 
4.1 INTESTINAL MOTILITY 
Borborygmi were evaluated on a scale from zero to four, with zero being no and four normal 
gut motility. 
The clinical examinations during the trial revealed an increase in borborygmi for the 
imidocarb with saline group (mean 2.64, ± SD 0.09). The imidocarb with atropine group on 
the other hand showed a decrease of gut motility (mean 1.86, ± SD 0.06) compared to the 
saline control group (mean 2.44, ± SD 0.09). The imidocarb with glycopyrrolate group 
presented an only mild decrease in borborygmi compared to the saline control group (mean 
2.22 and 2.44, ± SD 0.10 and 0.09, respectively). Paired t-tests showed that imidocarb 
produced a significant increase in hindgut borborygmi, compared with the saline control test, 
whereas atropine and glycopyrrolate medication produced a significant decrease in this 
parameter (p < 0.001). 
 
 
4.2 SIGNS OF COLIC AND DEFAECATION 
Four of six horses in the imidocarb and saline group only presented colic symptoms as in 
lying down, pawing, rolling and looking at the flank from between 30 min to five hours after 
injection of imidocarb. 
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Figure 4.2.1: Horse presenting colic after imidocarb with saline administration. 
 
 
These horses also showed severe diarrhoea between one to three hours after injection of 
imidocarb. Two horses had additional watery diarrhoea between two and three hours after 
drug administration. The number of defaecation was 23 times after imidocarb with saline 
injection, compared to twelve to 15 times in all other groups. 
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Figure 4.2.2: Horse showing colic after administration of imidocarb with saline. Note the 
marks of diarrhoea on the wall. 
 
 
Colic was not observed in the study group horses when imidocarb was administered 
concurrently with either atropine or glycopyrrolate. 
 
 
4.3 HEART AND RESPIRATORY RATE 
The average heart rate was highest in the horses administered imidocarb with atropine (mean 
47.62 per minute, ± SD 6.09) and also increased in the imidocarb with glycopyrrolate group 
(mean 38.42 per minute, ± SD 5.37). The imidocarb with saline group had a slightly elevated 
heart rate (mean 36.02 per minute, ± SD 5.08) and the heart rate of the saline control group 
was lowest (mean 33.75 per minute, ± SD 1.32). The significant heart rate increase in the 
imidocarb with atropine group (p < 0.001) was first noticed 30 min after drug administration 
and returned in four of six horses back to normal after further 30 min and ranged between 44 
and 96 beats per minute. The other two horses had an elevated pulse lasting until three hours 
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after injection. A significantly increased heart rate was also noted in five of six horses of the 
imidocarb with glycopyrrolate group. This increase lasted from 30 to a maximum of 90 
minutes after drug administration. The duration of elevated rates was comparably shorter than 
in the imidocarb with atropine group. 
The respiratory rate was significantly higher in the imidocarb with saline group (mean 16.37 
per minute, ± SD 2.76, p < 0.001), compared to all other groups (mean range 12.80 – 13.16 
per minute, ± SD 1.48 - 2.65). Those observations correlated in duration with the presentation 
of colic symptoms in the imidocarb with saline group. 
 
Table 4.3 1: Mean and ± SD of clinical parameters for each drug group. 
 
    
Imidocarb/ 
Atropine 
Imidocarb/ 
Saline 
Imidocarb/ 
Glycopyrrolate 
Saline/ 
Saline 
Borborygmi Mean: 1.86 2.64 2.22 2.44 
 ± SD: 0.06 0.09 0.10 0.09 
Heart rate Mean: 47.62 36.24 38.42 33.78 
(Beats/min) ± SD: 6.09 5.08 5.37 1.32 
Respiratory rate Mean: 13.16 16.37 12.83 12.80 
 (Breaths/min) ± SD: 2.65 2.76 1.81 1.48 
Figure 4.3.1: Means of heart rates 
Heart rate means (beats/min)
0
20
40
60
80
06:00 07:30 08:00 09:00 10:00 12:00 14:00 16:00 18:00 19:00
Time (h)
He
ar
t r
at
e 
(b
ea
ts
/m
in
)
Drug 1 Drug 2 Drug 3 Drug 4
 
 79
CLINICAL RESULTS 
Figure 4.3.2: Means of respiratory rates 
Respiratory rate means (breath/min)
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Drug combinations: Drug 1 = Imidocarb + atropine; drug 2 = imidocarb + saline; drug 3 = 
imidocarb + glycopyrrolate; drug 4 = saline control group 
 
 
Table 4.3 2: P-values of clinical parameters for each drug group (confidence interval 95%) 
 
P-values
Drug 1 vs. 
saline control 
Drug 2 vs. 
saline control 
Drug 3 vs. saline 
control 
Borborygmi p < 0.001 p < 0.001 p = 0.401 
Mean heart rate 
(Beats/min) p < 0.001 p = 0.006 p < 0.001 
Mean respiratory rate 
(Breaths/min) p = 0.024 p < 0.001 p = 0.939 
 
 
 
 
 
 
Drug combinations: Drug 1 = Imidocarb + atropine; drug 2 = imidocarb + saline; drug 3 = 
imidocarb + glycopyrrolate 
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4.4 INCIDENT BETWEEN TRIAL DAYS 
One horse suffered from an impaction of the pelvic flexure on a Sunday between trial weeks 
three and four. This followed treatment with imidocarb-saline combination of therapies. For 
the duration of the colic, this horse was therefore stabled at the Equine Clinic of the Faculty of 
Veterinary Science, Onderstepoort, South Africa. The horse coliced only mildly and the rectal 
examination revealed an impaction that was relatively small and softish. Therefore and to 
avoid any interference with the trial itself, the horse was only drenched initially with Epsom 
salts and water and then two-hourly with an oil-water mixture. Any other medication did not 
occur and the horse was walked and trotted alternately every hour for ten to 15 minutes. 
Sixteen hours later the horse started passing soft manure. It was then started on small portions 
of fresh grass, followed by soaked teff and lucerne and continued from Tuesday onwards with 
the normal trial procedures. 
 
 
4.5 PRELIMINARY CLINICAL CONCLUSIONS 
Colic signs were commonly observed in those horses treated with a combination of imidocarb 
and saline only, and this was accompanied by a relatively high incidence of diarrhoea and a 
significant increase in large intestinal borborygmi. These results suggest that imidocarb had a 
direct parasympathomimetic effect on large intestinal motility in the study subjects, with 
consequent frequent propulsive contractions, diarrhoea and colic. Pain in these subjects was 
evidenced by an increase in respiratory rate not seen when imidocarb was accompanied by 
medication with either atropine or glycopyrrolate. 
 
Both parasympatholytic agents atropine and glycopyrrolate reduced the effect of imidocarb on 
inducing diarrhoea, colic and increased respiratory rate, and would both therefore be 
considered beneficial in the clinical setting when treating babesiosis with imidocarb. 
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However, atropine caused a prolonged elevation of cardiovascular rate, suggesting that this 
compound may have greater side effects than glycopyrrolate. 
 
No marked cardiovascular or gastrointestinal effects were observed in those horses treated 
with the intravenous and intramuscular saline injections only. This suggests that the study 
procedure, and collection technique itself, was not accountable for any of those clinical signs 
attributed to pharmacological intervention. 
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CHAPTER 5 
LACTOSE 13C-UREIDE BREATH TEST FOR THE EFFECTS OF 
SPECIFIC BABESIOSIS TREATMENTS ON EQUINE ORO-CAECAL 
TRANSIT TIME 
 
5.1 DELTA VALUES 
The maximal increase in 13C abundance, expressed as delta values, ranged between the 
subjects between -15.71 and -13.30. The maximal delta value for each horse is shown in 
Table 5.1.1: 
 
 
Table 5.1.1: Maximal C delta of all subjects 
Max C delta            
Horse 1 Horse 7 Horse 3 Horse 4 Horse 5 Horse 6 Range:  
-15.71 -14.17 -14.68 -15.65 -14.14 -13.30 -13.30 to -15.71 
 
 
 
5.2 13C RECOVERY CURVES 
The 13C recovery curves for the induced lactose 13C-ureide isotope breath test were plotted for 
each individual. Curves of two subjects are shown as an example in Figures 5.2.1 – 5.2.8. 
Time in hours is plotted along the x-axis, and percentage dose recovery per hour of the stable 
isotope (PDR/hr) is shown along the y-axis. 
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Figure 5.2.1: Horse 7, week 1, Imidocarb 2.4 mg/kg with atropine 0.035 mg/kg 
OCTT = 10.463 hours 
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Figure 5.2.2: Horse 7, week 2, Imidocarb 2.4 mg/kg with saline 
OCTT = 4.914 hours 
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Figure 5.2.3: Horse 7, week 3, Saline control 
OCTT = 7.731 hours 
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Figure 5.2.4: Horse 7, week 4, Imidocarb 2.4 mg/kg with glycopyrrolate 0.0025 mg/kg 
OCTT = 5.506 hours 
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Figure 5.2.5: Horse 3, week 1, Imidocarb 2.4 mg/kg with saline 
OCTT = 6.980 hours 
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Figure 5.2.6: Horse 3, week 2, Saline control 
OCTT = 5.287 hours 
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Figure 5.2.7: Horse 3, week 3, Imidocarb 2.4 mg/kg with glycopyrrolate 0.0025 mg/kg 
OCTT = 5.314 hours 
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Figure 5.2.8: Horse 3, week 4, Imidocarb 2.4 mg/kg with atropine 0.035 mg/kg 
OCTT = 7.087 hours 
 
 
5.3 INTESTINAL PARAMETERS 
When OCTT was prolonged, as was the case with atropine, the mathematical curve fitting 
was difficult. In such cases the OCTT might be less accurate as it was largely based on the 
mathematical calculation using the least mean square method. This was due to the incomplete 
recovery of 13C at the end of breath sample collection. However, manual assistance of the 
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Solver function of Microsoft Office® Excel to find the minimum root mean square (RMS) 
values for the model led to successful results to the recovery data in each case. 
 
The mean (± SD) measurements for OCTT, t1/2, tlag, tmax for the different drug combinations 
were: Imidocarb 2.4mg/kg with atropine 0.035 mg/kg OCTT 12.98 h ± 8.22 h, t1/2 27.91 h ± 
22.16 h, tlag 16.75 h ± 11.58 h, tmax 24.89 h ± 19.24 h; Imidocarb 2.4 mg/kg with saline OCTT 
5.85 h ± 1.74 h, t1/2 11.36 h ± 3.25 h, tlag 7.29 h ± 2.03 h, tmax 10.85 h ± 2.99 h; Imidocarb 2.4 
mg/kg with glycopyrrolate 0.0025 mg/kg OCTT 6.10 h ± 1.01 h, t1/2 12.19 h ± 2.88 h, tlag 7.66 
h ± 1.21 h, tmax 11.03 h ± 2.25 h and saline OCTT 5.77 h ± 1.67 h, t1/2 14.19 h ± 3.55 h, tlag 
7.70 h ± 1.65 h, tmax 11.64 h ± 2.63 h. 
 
A summary of OCTT data is shown in Table 5.3.1 and individual mean OCTT parameters are 
presented in Tables 5.3.2. 
 
 
Table 5.3.1: Mean OCTT parameters for each drug group using 13C-LUBT (n = 6). 
  
Imidocarb/ 
Atropine (h) 
Imidocarb/ 
Saline (h) 
Imidocarb/ 
Glycopyrrolate (h) 
Saline 
Control (h) 
Mean OCTT 12,98 5,85 6,10 5,77 
±SD OCTT 8,22 1,74 1,01 1,67 
Mean t1/2 27,91 11,36 12,19 14,19 
±SD t1/2 22,16 3,25 2,88 3,55 
Mean tlag 16,75 7,29 7,66 7,70 
±SD tlag 11,58 2,03 1,21 1,65 
Mean tmax 24,89 10,85 11,03 11,64 
±SD tmax 19,24 2,99 2,25 2,63 
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Table 5.3.2: OCTT parameters of each subject using the 13C-LUBT. Weekly parameters are 
shown as well as the mean and SD (n = 4) for each subject. Data from week 3 of subject 4 and 
6 were withdrawn. The different drug combinations are shown in different colors: Saline = 
black, imidocarb/atropine = red, imidocarb/saline = green, imidocarb/glycopyrrolate = blue. 
 
Horse 1 OCTT (h) t1/2 tlag tmax
Week 1 3.35 18.72 6.35 11.95 
Week 2 6.09 17.47 8.84 14.75 
Week 3 5.39 14.44 7.63 12.45 
Week 4 9.28 12.25 10.14 11.99 
Mean (h) 6.03 15.72 8.24 12.79 
± SD 2.46 2.93 1.62 1.33 
 
Horse 7 OCTT (h) t1/2 tlag tmax
Week 1 10.46 15.79 11.93 15.12 
Week 2 4.91 8.27 5.72 7.46 
Week 3 7.73 16.31 10.00 14.94 
Week 4 5.51 10.83 6.70 9.19 
Mean (h) 7.15 12.83 8.56 11.68 
± SD 2.52 3.88 2.91 3.94 
 
Horse 3 OCTT (h) t1/2 tlag tmax
Week 1 6.98 10.40 7.93 10.00 
Week 2 5.29 11.17 6.50 8.88 
Week 3 5.31 11.47 6.93 10.45 
Week 4 7.09 12.75 8.63 12.01 
Mean (h) 6.17 11.81 7.47 10.33 
± SD 1.00 0.69 0.95 1.30 
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Horse 4 OCTT (h) t1/2 tlag tmax
Week 1 7.11 12.67 8.65 12.00 
Week 2 27.47 63.86 36.82 57.17 
Week 3     
Week 4 4.80 9.69 6.11 8.96 
Mean (h) 13.13 24.03 13.74 26.04 
± SD 12.48 22.30 11.10 27.00 
 
Horse 5 OCTT (h) t1/2 tlag tmax
Week 1 10.60 34.90 16.23 28.17 
Week 2 7.51 11.83 8.71 11.32 
Week 3 8.83 16.35 10.89 15.38 
Week 4 6.86 14.54 8.88 13.30 
Mean (h) 8.45 19.40 11.18 17.04 
± SD 1.65 10.49 3.51 7.60 
 
Horse 6 OCTT (h) t1/2 tlag tmax
Week 1 5.64 10.19 6.75 9.12 
Week 2 4.18 9.04 5.45 8.23 
Week 3     
Week 4 5.05 8.90 6.12 8.45 
Mean (h) 4.96 9.37 6.11 8.60 
± SD 0.74 0.71 0.65 0.47 
 
5.4 SIGNIFICANCE OF RESULTS 
Analysis of variance (ANOVA) was used to calculate the significance of the drug treatments 
on the measured parameters of gastrointestinal motility. The drug combinations were assumed 
to have significant difference to the saline controls, if the p-value was < 0.05. OCTT, tmax, t1/2, 
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tlag had the values p = 0.017, p = 0.030, p = 0.045 and p = 0.019 respectively. The p-values for 
each horse and different weeks were all above 0.05. This indicates that the results of this 
study were influenced significantly only by the different drug combinations, and not by any 
temporal effects during the study period. The p-values are shown in Table 5.4.1. 
 
Table 5.4.1: P-values of different factors. 
  P OCTT P t1/2 P tlag (10%) P tmax
Horse 0.20 0.27 0.185 0.20 
Weeks 0.18 0.20 0.154 0.16 
Drugs 0.017 0.05 0.019 0.03 
 
Furthermore the differences between each drug combination for OCTT, tmax, t1/2 and tlag were 
evaluated for significance using the t–test, or in cases where the results were not normally 
distributed the Mann – Whitney Rank Sum Test. 
 
5.4.1 Effects on OCTT 
For OCTT the p-values were significant for Imidocarb 2.4 mg/kg with atropine 0.035 mg/kg 
(drug 1) versus Imidocarb 2.4mg/kg with saline (drug 2), drug 1 versus Imidocarb 2.4 mg/kg 
with glycopyrrolate 0.0025 mg/kg (drug 3) and drug 1 versus saline (drug 4) with p = 0.009, 
0.017 and 0.016 respectively. Drug 2 versus drug 3 (p = 0.768), drug 2 versus drug 4 (p = 
0.944) and drug 3 versus drug 4 (p = 0.700) showed no significance, but the power of these 
tests was below 0.8, which shows a likelihood of non detection of significant differences 
when one might actually exist there. 
 
5.4.2 Effects on tmax
Only the p-value (p = 0.030) of the comparison of drug 1 versus drug 3 presented significance 
for tmax. Drug 1 vs. drug 2 (p = 0.082), drug 1 vs. drug 4 (p = 0.095), drug 2 vs. drug 3 (p = 
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0.696), drug 2 vs. drug 4 (p = 0.493) and drug 3 vs. drug 4 (p = 0.687) were above 
significance. Also these results present a power of the test of below 0.8, which suggests 
interpretation with caution. Furthermore no great differences in the median values between 
each group were presented in the latter values. This difference could be explained with the 
random sampling variability. 
 
5.4.3 Effects on t1/2
T1/2 had no significance in any of its p-values, which could be either due to the low power of 
these test or the small difference in the median values between two groups. The p-values of 
drug 1 vs. drug 2, drug 1 vs. drug 3, drug 1 vs. drug 4, drug 2 vs. drug 3, drug 2 vs. drug 4 and 
drug 3 vs. drug 4 are 0.101, 0.116, 0.209, 0.651, 0.201 and 0.329 respectively. 
 
5.4.4 Effects on tlag
The p-values for tlag were significant for drug 1 vs. drug 2 (p = 0.017), drug 1 vs. drug 3 (p = 
0.030) and drug 1 vs. drug 4 (p = 0.032) and not significant for drug 2 vs. drug 3 (p = 0.710), 
drug 2 vs. drug 4 (p = 0.727) and drug 3 vs. drug 4 (p = 0.966). The power of the tests with 
insignificant p-values was also in this case below 0.8 and the differences in median values 
between two groups were also not great. 
 
The p-values are presented in Table 5.4.2. OCTT, t1/2, tlag and tmax are presented in comparison 
between each drug combination in Figures 5.4.1. 
Table 5.4.2: P-values of comparison between drug combination groups. 
Drug comparison P OCTT P t1/2 P tlag (10%) P tmax
D1 vs. D2 0.009 0.101 0.017 0.082 
D1 vs. D3 0.017 0.116 0.030 0.030 
D1 vs. D4 0.016 0.209 0.032 0.095 
D2 vs. D3 0.768 0.651 0.710 0.696 
D2 vs. D4 0.944 0.201 0.727 0.493 
D3 vs. D4 0.700 0.329 0.966 0.687 
Significant differences are highlighted in red. 
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Figures 5.4.1: Comparison of drug combinations with OCTT, tmax, t1/2 and tlag. 
 
 
 
 
Drug 1: Imidocarb with atropine; Drug 2: Imidocarb with saline; Drug 3: Imidocarb with 
glycopyrrolate; Drug 4: Saline control 
 
 
5.5 PRELIMINARY CONCLUSIONS ON EFFECT OF DRUG COMBINATIONS ON 
PARAMETERS OF GASTROINTESTINAL TRANSIT 
Using the induced lactose 13C-ureide breath test it was shown in this section of the study, that 
concurrent medication of imidocarb-treated horses with atropine resulted in a significant 
prolongation of the oro-caecal transit time of the chosen test meal. Prolongation of other 
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parameters, including caecal half-transit time, also occurred but these changes were not 
significant due to the wide variance in these parameters. 
 
Contrary to expectation, imidocarb dipriopionate itself did not result in significant reduction 
in the parameter of OCTT when compared with saline controls. Similarly, combined 
treatment of horses in this study with both imidocarb dipropionate and glycopyrrolate did not 
result in a significant reduction in oro-caecal transit or caecal half-emptying time when 
compared with the saline controls. Those horses treated with the atropine/imidocarb 
combination did have significant prolongation of OCTT when compared to those treated with 
imidocarb and the shorter acting parasympatholytic agent, glycopyrrolate. This latter finding 
suggests that the different parasympatholytic agents have different mechanisms of action on 
the equine small intestine, an important clinical finding that has not previously been 
recognised. 
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CHAPTER 6 
GENERAL DISCUSSION AND CONCLUSION 
 
6.1 EFFECT OF SPECIFIC BABESIOSIS TREATMENT ON EQUINE ORO-
CAECAL TRANSIT TIME 
6.1.1 Validation of study methods and protocol 
The effect of imidocarb administration alone and in combination with atropine and 
glycopyrrolate on oro-caecal transit time (OCTT) was assessed using the lactose 13C-ureide 
breath test (LUBT). The LUBT is a valid method for measurement of OCTT in man (Wutzke 
et al. 1997) and horses (Sutton et al. 2000). Although horses older than three years may be 
lactose intolerant (Roberts 1975), this has not been shown to be a rate-limiting factor in vitro 
for the digestion of lactose 13C-ureide labels (Sutton 2003). It was shown in a previous study 
that the lactose ureide (LU) bond is exclusively split by Clostridium innocuum (Wutzke et al. 
1998; Mohr et al. 1999). Furthermore it was reported that the fermentation of lactose ureide is 
restricted to the caecum in horses and that prior exposure to lactose 12C-ureide increases the 
rate of microbial lactose 13C-ureide digestion significantly (Sutton 2003) and therefore 
increases the appearance of tracer in breath (Morrison et al. 2003). In addition, as there is no 
osmotic effect on motility (Ruemmele et al. 1997), LU is therefore an ideal tracer for 
measuring OCTT. 
A minimum of 14 hours of prior exposure to lactose 12C-ureide was shown to maximise 
subsequent 13CO2 production rate, and this was considered due to maximal induction of the 
requisite bacterial activity in the caecum (Sutton 2003). 
 
The horses were stabled from two days prior to breath collection study days and were not 
exercised at all for the entire duration of the trial to avoid increase of background enrichment 
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of expired CO2 due to changes in the metabolic state (Schoeller et al. 1977; Wolfe et al. 
1984). 
Unlabelled lactose ureide was fed a day prior to the ingestion of the labelled isotope test meal, 
as it results in a greater 13CO2-enrichment, due to the induction of microbial enzyme activity 
(Wutzke et al. 1998). The horses were starved overnight to decrease the baseline isotope ratio 
of breath CO2 (Schoeller et al. 1977; Schoeller et al. 1984). Furthermore no food intake was 
allowed during the trials as an earlier study found it to shorten OCTT (Priebe et al. 2004). 
Duplicate expiratory breath samples were collected from each horse using a modified 
Aeromask® (Trudell Medical International, Ontario, Canada). Each sampling collection took 
about two minutes. Horse’s breathing (Orr et al. 1975) as well as respiratory and heart rate are 
not influenced by respiratory gas collection masks in non exercising horses (Evans et al. 
1988). 
Four different drug combinations were tested (imidocarb 2.4 mg/kg IM with atropine 0.035 
mg/kg IV, imidocarb 2.4 mg/kg IM with saline IV, imidocarb 2.4 mg/kg IM with 
glycopyrrolate 0.0025 mg/kg IV and saline IM with saline IV) in a randomised, double 
blinded trial on six clinically healthy subjects (two ponies, four horses). The doses of the 
different drugs chosen in this study were based on reports taken from various earlier studies 
(Kuttler 1980; Singh et al. 1996; Heerden 1996; Phipps et al. 1996; Singh et al. 1997a; Singh 
et al. 1997b; Sutton et al. 2002; Belloli et al. 2002; Donnellan 2006). 
Imidocarb is the drug of choice for equine babesiosis (Donnellan et al. 2003b) at a 
recommended dosage of 2.4 mg/kg bwt by intramuscular administration (Belloli et al. 2002). 
 
6.1.2 Discussion of study results 
Imidocarb did not produce a significant decrease in equine oro-caecal transit time (OCTT), 
when compared with the co-administration of glycopyrrolate group or the saline control 
group. This result was surprising as the cholinergic acting imidocarb could be expected to 
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hasten transit time due to an increase in circular and longitudinal smooth muscle activity 
(Malone et al. 1996). Donnellan (2006) on the other hand, using transrectal ultrasonographic 
measurement of intestinal motility, did not find an increase in intestinal contractions in the 
imidocarb group (Donnellan 2006), which could explain our findings in the horses given 
imidocarb with saline. Donnellan’s study assessed intestinal motility using ultrasonography 
after administration of four different drug therapies (imidocarb 2.4 mg/kg IM with saline IV, 
imidocarb 2.4 mg/kg IM with atropine 0.02 mg/kg IV, imidocarb 2.4 mg/kg IM with 
glycopyrrolate 0.0025 mg/kg IV and saline IM with saline IV). It was clearly proven in this 
current study that the co-administration of atropine increased OCTT significantly compared to 
the other drug combinations and saline group. Donnellan’s (2006) similar study found a 
decrease in intestinal contractions in the atropine group (Donnellan 2006). A decrease of 
intestinal contractions could lead to chyme not being forwarded and therefore leading to an 
increased OCTT. 
 
The power of our statistical calculation was low for the results with a p-value above 0.05. 
This indicates a likelihood of not detecting a significant difference when one actually exists. It 
is possible that as the number of subjects used for this study was low, a higher number might 
have shown clearly interpretable results. Furthermore, the number of collected breath samples 
for the drug combination imidocarb with saline and imidocarb with atropine were additionally 
minimised as two horses had to be excluded from a single trial day. This was due to the breath 
test results as well as the clinical observation of heart rate, faecal output and borborygmi that 
strongly led to the suspicion of the blindly administered drug combination of imidocarb with 
saline and imidocarb with atropine having been mixed up in these two horses. 
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6.1.3 Potential confounding factors in study interpretation 
Human studies have shown that gender (Degen et al. 1996; Graff et al. 2001) and age (Graff 
et al. 2001) have an influence on intestinal transit time. Although the exact effect of these 
parameters is not known in horses, each subject in this study acted as its own control, thus 
eliminating the effects of any such confounding factors. 
 
The accuracy of 13C isotope breath tests depends on a constant basal 13CO2 production during 
the test period. Equine diet, particularly the natural background 13C of that diet (Morrison et 
al. 2000) and exercise (Rating et al. 1997) can both influence this basal 13CO2 production by 
metabolic fluctuation. Therefore horses were starved before and during the trial and not 
exercised for the entire trial period. It has been shown elsewere that dehydration does not 
influence OCTT (van Nieuwenhoven et al. 2000). However, another factor that might have 
influenced the results of this study is the fact that the horses used were allowed to graze on 
pasture during the wash out period between the days of breath sample collection. This factor 
might have influenced gut motility, as it represented changes in both dietary grass intake and 
relative exercise levels. We decided before trial to take this risk, as we assumed this influence 
might only be a minor component and also tried to find a balance in preventing colic due to 
impaction and a stable daily routine for the horse with minimal effects on gut motility. The 
prevention of impaction colics seemed very important as the study was done in May and June 
which correlates with the drought season in the north of South Africa, during which a peak of 
colics due to impaction can be clinically observed in equine practice (personal 
communication, Dr. Sutton). The progressive effect of any such confounding factor on the 
longitudinal results of the study was minimised also by the active randomisation of the drug 
therapies for each horse with time (see Appendix A). 
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Grazing during the study period between trial days might have increased the consumption of 
C4 enriched tropical plants such as the Kikuyu grass that is common on pasture in this area. 
This likely led to an increase of natural background 13C (Craig 1957; Morrison et al. 2000) in 
expiratory breath. The baseline 13C abundance expressed as delta values ranged from -21.49 
to -16.90. The maximal increase in 13C abundance between the subjects was found to be 
between -13.30 and -15.71. This represents relatively close values for baseline and maximal 
increase measurements. However, increases in breath 13CO2 were measured against the 13CO2 
baseline output in each case, measured before the isotope substrate was fed. Initial 
measurement, taken in the test subjects under test conditions, after ingestion of the test meal 
without enrichment by the isotope, showed a tendency for baseline 13C production to fall with 
time under test conditions. The cause for this was not clear but may have been caused by the 
metabolism of the test meal which was lower in 13C content than residual carbohydrate stores 
in the test subjects. In order to limit this variable from future studies it would be necessary to 
either measure basal 13C-output in a larger number of individuals over time, and to plot its 
mean change under test conditions, or to supplement the test meal with a much higher dose of 
13C-isotope so as minimise the effect of any fluctuation in background output. This latter 
solution is the most straightforward, but was too expensive for the means of this study. 
 
It has been proposed in a study to measure individual CO2 production (VCO2) for calculating 
an accurate percentage dose recovered (PDR) (Amarri et al. 1998). As this was impractical 
here, VCO2 was calculated in this study, based on reported studies in ponies (Orr et al. 1975) 
and horses (Gallivan et al. 1989). 
 
The point of rise of concentration in exhaled breath, was the same in other breath test studies 
using either direct plotting or cumulative sum plotting of PDR/h exhaled breath data (Brown 
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et al. 1987; Sutton 2003). Therefore only the commoner approach of direct plotting was used 
in this study, with use of least means squares plots to fit the power regression curve. 
Although several digestive processes might be part of the OCTT, our results seemed to have 
been described very well by a one-curve model. Therefore we did not apply an elsewhere 
described two-curve model fit to our data (Vickers et al. 2001; Christian et al. 2002b). 
 
 
6.2 PHYSIOLOGICAL INTERPRETATION OF CLINICAL INFORMATION OBSERVED 
DURING THE STUDY 
In this study four horses developed colic signs, including pawing, lying down and rolling after 
administration of imidocarb with saline. This was expected to occur as colic (Frerichs et al. 
1973; Frerichs 1977; Meyer et al. 2005) and also diarrhoea was observed in earlier studies in 
both horses (Carbrey et al. 1971) and goats (Corrier et al. 1976). The symptoms started 30 
min after drug administration and lasted up to five hours and correlated to the occurrence of 
watery diarrhoea. Phipps (1996) and Adams (1981) reported similar findings for the duration 
of colic signs (Adams 1981; Phipps et al. 1996) after administration of imidocarb. Corrier 
(1976) observed in his study in goats the diarrhoea to last between three to five hours (Corrier 
et al. 1976). The duration of systemic side effects could be associated with a high plasma 
concentration of imidocarb. Belloli et al. (2002) found imidocarb to be rapidly absorbed and 
to be detectable in the plasma concentration ten minutes after administration with a following 
plateau level for two hours and subsequent fast distribution but slow elimination phase 
(Belloli et al. 2002). Adams (1981) also found imidocarb to increase rapidly after 
administration and to decline over the following two to four hours (Adams 1981). 
Another study reported mild diarrhoea and abdominal discomfort in horses given lactose 
(Roberts 1975). Lactose itself does not seem to have caused any of these in our study as only 
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some subjects given imidocarb with saline presented these symptoms, and the quantity of 
lactose produced by digestion of the labelled isotope was extremely small. 
In contrast to Donnellan’s study we did not observe any signs of colic after administration of 
imidocarb with atropine (Donnellan 2006). This might be explained by the higher dose of 
atropine used in our study (0.035 mg/kg IV) and could lead to the assumption that a higher 
dose of atropine than 0.02 mg/kg (Donnellan 2006) would be necessary to prevent side effects 
of imidocarb administration. On the other hand the dose of atropine should not be too high 
either, as another study assessing the side effects of atropine administration, observed colic 
symptoms due to atropine administration starting from 0.044 mg/kg bwt (Ducharme et al. 
1983). 
One horse in the study suffered colic due to an impaction of the pelvic flexure. This occurred 
more likely due to the limited exercise and environmental influences than due to side effects 
of atropine administration, as the horse had only received atropine 17 days prior to the colic. 
 
On auscultation of gastrointestinal motility a significant increase in borborygmi was noted in 
the group that had imidocarb alone. This confirms the finding of other studies, where the use 
of imidocarb caused “violent peristalsis” (Adams 1981) or hypermotility of the 
gastrointestinal tract (Frerichs et al. 1973; Frerichs et al. 1974). Atropine is known to reduce 
gastrointestinal motility (Ducharme et al. 1983; Roberts et al. 1986; Imbimbo et al. 1990; 
Adams 2001; Sutton et al. 2002), even when administered only by topical or subconjunctival 
application (Williams et al. 2000) and to delay gastric emptying (Imbimbo et al. 1990; Sutton 
et al. 2002). In this study the imidocarb with atropine group presented a significant decrease 
in borborygmi and the imidocarb with glycopyrrolate group presented gut sounds similar to 
the saline group. Glycopyrrolate also has a dose dependent (Roberts et al. 1986; Singh et al. 
1996) effect on decreasing gut motility (Singh et al. 1997a; Singh et al. 1997b). Therefore 
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when given with imidocarb the increasing effect of imidocarb and the decreasing feature of 
glycopyrrolate seem to level each other. 
The administration of imidocarb with atropine led to a tachycardia for up to three hours. This 
finding is in agreement with another study that evaluated effects of atropine on end-organs 
(Mirakhur and Dundee 1980). The heart rate of the imidocarb with glycopyrrolate group was 
increased only for one hour and not at all increased in one horse of the latter group. This is a 
common and sometimes even desired finding after the use of atropine (Gasthuys et al. 1990; 
Imbimbo et al. 1990; Weil et al. 1997; Lidums et al. 2000; Adams 2001; Sutton et al. 2002) 
or glycopyrrolate (Singh et al. 1996; Singh et al. 1997a; Singh et al. 1997b; Adams 2001). 
Singh et al. (1996) found an increase in heart rate after administration of 2.5 µg/mg bwt 
glycopyrrolate as premedication for anaesthesia (Singh et al. 1996), or as a premedication for 
sedation with xylazine (Singh et al. 1997b). However, in another of their studies using the 
same dose no change in heart rate occurred (Singh et al. 1997a). 
Imidocarb’s adverse effects might be due to excessive cholinergic action (Abdullah et al. 
1984) on the large intestine. 
 
6.3 CONCLUSION 
The breath test collection technique was easy to perform and excellently tolerated by the 
horses used in this study. The ability of atropine and glycopyrrolate to prevent the side effects 
of imidocarb administration and the effect on oro-caecal transit time (OCTT) of all these 
drugs were assessed in this study. No significant changes in OCTT were noted with imidocarb 
with glycopyrrolate or imidocarb alone. Atropine on the other hand showed an increase in 
OCTT. However, both atropine and glycopyrrolate improved the clinical side effects of 
imidocarb. Atropine showed more inhibitory effects on the gastrointestinal tract, reducing 
borborygmi compared to glycopyrrolate. Also the heart rate was increased for a longer 
duration with atropine than with the use of glycopyrrolate. 
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The fact that glycopyrrolate ameliorated the clinical side effects of imidocarb, namely 
diarrhoea and colic with increased intestinal borborygmi, without significantly changing 
OCTT, suggests that its predominant mechanism of action in the horse (at 0.0025 mg/kg IV) 
is on the large intestine. Conversely atropine (at 0.035 mg/kg IV) was shown to increase 
OCTT in this study, in addition to significantly decreasing intestinal borborygmi and 
prolonging caecal half-transit time. This latter finding suggests that atropine has potent effects 
on both equine small and large intestine. As imidocarb alone did not cause significant 
reductions in the rate of oro-caecal transit of the chosen test meal, it must be concluded from 
this study that its side effects result principally from direct stimulation of large intestinal 
hypermotility, colic and diarrhoea, rather than modulation of small intestinal motility. 
 
This method of evaluating effects on equine gastrointestinal transit time could be applied to 
further studies. The emphasis could be put on different parts of the gastrointestinal tract, using 
different substrates. It would be desirable for the future, if further research in this field would 
be done. Although LU and IRMS analysis are expensive techniques, this non-invasive 
modality will hopefully be of future diagnostic importance in the investigation of cases with 
recurrent colic and in clinical pharmacology trials. 
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APPENDIX A: RANDOMISATION OF TREATMENT PROTOCOL 
Injection 
Protocol Horse 1 Horse 7 Horse 3 Horse 4 Horse 5 Horse 6 Summary
First week A C B D C A ABCDAC 
Second week D B A C D B ABCDBD 
Third week B A D A B C ABCDAB 
Fourth week C D C B A D ABCDCD
        
A Saline control       
B Imidocarb 2.4 mg/kg IM / saline IV      
C Imidocarb 2.4 mg/kg IM / Atropine 0.035 mg/kg IV     
D Imidocarb 2.4 mg/kg IM / Glycopyrrolate 0.0025 mg/kg IV    
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Equine babesiosis is an infectious tick-borne disease that leads to haemolytic anaemia. The 
parasites Theileria equi and Babesia caballi cause acute, subacute or chronic diseases in 
Equidae, neonatal babesiosis or abortion in mares and death can occur. 
Imidocarb dipropionate is the drug of choice to control the disease in Equidae. Due to its 
cholinergic properties, systemic side effects include depression, intestinal hypermotility, and 
colic and lateral recumbency may occur. 
For avoidance of these undesired effects, prior administration of either atropine or 
glycopyrrolate is proposed to ameliorate side effects. 
Atropine and glycopyrrolate are both anticholinergic drugs that inhibit gastrointestinal 
motility. Glycopyrrolate is preferred over atropine sulphate as it has increased water solubility 
and thus does not cross the blood-brain barrier. 
 
Previous studies have validated the induced lactose 13C-ureide breath test (LUBT) against 
enterocolonic scintigraphy for the measurement of oro-caecal transit time (OCTT) in humans 
(Geypens et al. 1999) and the test has been validated in vitro for this measurement in horses 
(Sutton 2003). It was concluded to be a valid alternative to scintigraphy for OCTT 
measurements in humans (Geypens et al. 1999) and a superior technique to the H2 breath 
production test in horses (Sutton 2003). 
 
The aims of this study were to improve the knowledge of the specific effects of imidocarb 
treatment on equine OCTT, to quantify the effects of premedication with atropine or 
glycopyrrolate and to develop/validate a clinical protocol for treatment of babesiosis that 
results in minimal gastrointestinal complications. 
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The relative effects of three drug therapies (imidocarb dipropionate 2.4 mg/kg IM with saline 
IV (I/S); imidocarb dipropionate 2.4 mg/kg IM with atropine 0.035 mg/kg IV (I/A); 
imidocarb dipropionate 2.4 mg/kg IM with glycopyrrolate 0.0025 mg/kg IV (I/G)) were 
measured against a saline control (SC) (saline IM with saline IV) in a randomised treatment 
protocol. 
The relative effects of these compounds on OCTT were measured in six healthy horses using 
the induced lactose 13C-ureide breath test (LUBT). Duplicate breath samples were taken and 
the 13C:12C ratio of the breath samples was measured using continuous flow isotope ratio mass 
spectrometry (CF-IRMS). Sequential exhaled breath delta 13C-values were used to provide an 
estimate of OCTT. 
 
The mean (± SD) measurements for OCTT for the different drug combinations were: I/A 
12.98 h ± 8.22 h, I/S 5.85 h ± 1.74 h, I/G 6.10 h ± 1.01 h and SC 5.77 h ± 1.67 h. Only OCTT 
of I/A was significantly increased, compared to the other drug combinations. Mean OCTT in 
the horses treated with I/S showed a non significant tendency to decrease. 
 
In our clinical observations I/S caused colic and diarrhoea in four of six horses. Colic 
symptoms were presented with pawing, looking at flank and rolling, lasting from 30 min to 
five hours after injection. Gut motility was auscultated on a scale from zero (none) to four 
(normal). It was increased (mean 2.64, ± SD 0.09) after administration of I/S and decreased 
(mean 1.86, ± SD 0.06) after I/A was given. 
The average heart rate was highest in the horses administered I/A (mean 47.62, ± SD 6.09) 
and less so in the I/G group (mean 38.42, ± SD 5.37) as well as the I/S group (mean 36.24, ± 
SD 5.08). The heart rate of the SC group was lowest (mean 33.78, ± SD 1.32). 
The respiratory rate was notable higher in the I/S group (mean 16.37, ± SD 2.76), compared 
to all other groups (mean range 12.80 – 13.16, ± SD 1.48 - 2.65). 
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The breath test collection technique was easy to perform and excellently tolerated by the 
horses used in this study. I/S did not produce a significant decrease in OCTT, whereas 
atropine caused a significant increase in OCTT. However, both atropine and glycopyrrolate 
ameliorated the clinical side effects of imidocarb. Since atropine showed more inhibitory 
effects on the gastrointestinal tract, as well as causing an increased OCTT, glycopyrrolate is 
therefore preferable as pre-medication for imidocarb to minimise undesirable side effects. As 
imidocarb dipropionate treatment did not cause a significant decrease in equine OCTT, its 
principal effect on the equine gastrointestinal tract appears to be to increase large rather than 
small intestinal motility. Similarly, glycopyrrolate ameliorated the effects of imidocarb by 
reducing large intestinal effects without causing a significant delay in small intestinal (oro-
caecal) transit, whereas atropine caused a significant increase in OCTT and reduction in 
intestinal borborygmi. 
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Equine Babesiose ist eine infektiöse Erkrankung, die durch Zecken übertragen wird und zur 
hämolytischen Anämie führt. Ausgelöst wird diese Erkrankung in Equiden durch die 
Parasiten Theileria equi und Babesia caballi. Es kommen akute, subakute oder chronische 
Formen vor, die zum Tode des Tieres führen können. Desweiteren kann es zu neonataler 
Babesiose bei Fohlen und Aborten bei Stuten kommen. 
Imidocarb Diproprionat ist das Medikament der Wahl für die Equine Babesiose. Aufgrund 
seiner cholinergen Eigenschaften, können systemische Nebenwirkungen wie Depression, 
gastrointestinale Hypermotiliät, Diarrhoea, Kolik und Festliegen auftreten. 
Eine zusätzliche Verabreichung von Atropin oder Glykopyrrolat ist zur Vermeidung der 
unerwünschten Nebenwirkungen empfohlen. 
Atropin und Glycopyrrolat gehören zu der Gruppe der anticholinergen Pharmaka und haben 
daher eine hemmende Wirkung auf die gastrointestinale Motilität. 
Glycopyrrolat ist gegenüber Atropin bevorzugt, da es eine erhöhte Wasserlöslichkeit aufweist 
und folglich die Blut-Hirn Schranke nicht überschreitet. 
 
Frühere Studien haben den Laktose 13C-Ureid Atemtest mit der enterokolonischen 
Szintigrafie bezüglich Messungen von oro-zäkalen Transitzeiten in Pferden verglichen. Der 
Laktose 13C-Ureid Atemtest wurde gegenüber der Szintigrafie zu einer gültigen Alternative 
zur Messung von oro-zäkalen Transitzeiten erklärt. 
 
Das Ziel unserer Studie lag darin, das Wissen über die spezifische Wirkung auf die oro-zäkale 
Transitzeit nach der Gabe von Imidocarb zu verbessern. Desweiteren wurde die Wirkung der 
Premedikation mit Atropin und Glykopyrrolat untersucht und ein Therapievorschlag für die 
Babesiose erarbeitet, der minimale gastrointestinale Nebenwirkungen auslöst. 
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In unserer randomisierten  Studie wurden die Wirkungen von drei medikamentösen 
Therapiemöglichkeiten (Imidocarb Dipropionat 2,4 mg/kg IM und Kochsalzlösung IV (I/S); 
Imidocarb Dipropionat 2,4 mg/kg IM und Atropin 0,035 mg/kg IV (I/A); Imidocarb 
Dipropionat 2.4 mg/kg IM und Glykopyrrolat 0,0025 mg/kg IV (I/G)) mit einer 
Kontollgruppe (SC) (Kochsalzlösung IM und Kochsalzlösung IV) verglichen. 
Um die ungefähre Wirkung dieser Medikamentenkombinationen auf die oro-zäkale 
Transitzeit zu messen, haben wir den Laktose 13C-Ureid Atemtest in sechs klinisch gesunden 
Pferden angewandt. Doppelte Proben der Ausatemluft wurden gesammelt und das Verhältnis 
von 13C:12C wurde mittels CF-IRMS (continuous flow isotope ratio mass spectrometry) 
gemessen. 
Im Mittel (± SD) waren die Messungen der oro-zäkalen Transitzeit für die verschiedenen 
Medikamentenkombinationen: I/A 12,98 h ± 8,22 h, I/S 5,85 h ± 1,74 h, I/G 6,10 h ± 1,01 h 
und 5,77 h ± 1,67 h für die SC-Gruppe. Verglichen zu den anderen Medikamentengruppen, 
war nur die oro-zäkale Transitzeit für die Gruppe I/A signifikant verlängert. Für die I/S 
Kombination konnte nur eine nicht signifikante Tendenz zu einer Verkürzung der oro-zäkale 
Transitzeit festgestellt werden. 
 
Bei den klinischen Beobachtungen fiel auf, dass die Gabe von I/S in vier von sechs Pferden, 
Kolik mit Diarrhoea auslöste. Die Koliksymptome waren Scharren mit den Hufen, zur Flanke 
Sehen und Wälzen und traten zwischen 30 min und fünf Stunden nach Medikamentengabe 
auf. 
Gastrointestinale Motilität wurde auskultiert und auf einer Skala von Null (keine) bis vier 
(normal) bewertet. Nach der Gabe von I/S wurde eine erhöhte (im Mittel 2,64; SD ± 0,09) 
Motilität festgestellt und nach der Verabreichung von I/A, eine verminderte (im Mittel 1,86; 
SD ± 0,06). 
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Die durchschnittliche Herzfrequenz war in der I/A Gruppe am höchsten (im Mittel 47,62, SD 
± 6,09) und etwas niedriger in der I/G Gruppe (im Mittel 38,42; SD ± 5,37), wie auch in der 
I/S (im Mittel 36,24; SD ± 5,08). Die Herzfrequenzen der SC_Gruppe (im Mittel 33,78; SD ± 
1,32) lagen am niedrigsten. 
Die Atemfrequenz war, verglichen mit den anderen Gruppen (im Mittel 12,80 – 13,16, ± SD 
1,48 – 2,65), in der I/S Gruppe merkbar erhöht (im Mittel 16,37, SD ± 2,76). 
 
Die Sammlung der Atemgasproben war leicht durchführbar und wurde von den Pferden dieser 
Studie hervorragend toleriert. 
Die Gabe von I/S zeigte keine signifikante Verkürzung der oro-zäkalen Transitzeit. Die 
Verabreichung von I/A führte zu einer signifikanten Verlängerung der oro-zäkalen 
Transitzeit. 
Glykopyrrolat und Atropin verbesserten die klinischen Nebenwirkungen von Imidocarb. 
Atropin zeigte jedoch eine hemmendere Wirkung auf den gastrointestinalen Trakt und 
verlängerte ausserdem die oro-zäkale Transitzeit. Zur Verhinderung von Nebenwirkungen ist 
daher Glykopyrrolat zur Premedikation für die Verabreichung von Imidocarb empfohlen. 
Nachdem Imidocarb keine signifikante Verkürzung der equinen oro-zökalen Transitzeit 
verursacht hat, ist anzunehmen, dass es eher eine vermehrte Motilität des Dickdarms als des 
Dünndarms verursacht. Ähnlich verhält es sich mit dem Glykopyrrolat, das die 
Nebenwirkungen von Imidocarb verbesserte, indem es die Effekte des Dickdarmes 
verminderte, ohne eine bedeutende Verzögerung der Dünndarm (oro-zökalen) Transitzeit zu 
verursachen. Atropine hingegen verursachte eine signifikante Verlängerung der oro-zökalen 
Transitzeit und reduzierte die Darmgeräusche. 
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